This is a non-core endpoint: only basic statistics are computed.
Failure of sterile precautions during surgical operation
VWXY20_STERI_VAROT_PETTA_KIRURGISEN_TAI_MUUN_LAAKETIETEELLISEN_HOIDON_AIKANA
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
117 |
4. Check minimum number of eventsNone |
117 |
5. Include endpointsNone |
117 |
6. Filter based on genotype QC (FinnGen only) |
111 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF9
- Parent code in ICD-10
- Y6
Similar endpoints
↥List of similar endpoints to
Failure of sterile precautions during surgical operation
based on the number of shared cases.
Similar with more cases:
- Misadventures to patients during surgical and medical care
- Complications of medical and surgical care
- External causes of morbidity and mortality
- Injury, poisoning and certain other consequences of external causes
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 111 | 61 | 50 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 65.96 | 63.84 | 68.54 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 117
- Matched controls
- 1170
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
60.9
112.8
93
70
Y62.0
ICD-10 Finland
Failure of sterile precautions during surgical and medical care during surgical operation
+∞
82.2
69
*
Y62.9
ICD-10 Finland
Failure of sterile precautions during surgical and medical care during unspecified surgical and medical care
+∞
24.9
23
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.6
17.8
48
130
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
7.7
16.3
26
42
J04AB02
ATC
rifampicin; systemic
65.6
15.2
17
*
SPAT1255
SPAT
Intravenous administration of medicine
7.9
15.1
23
35
SPAT1144
SPAT
Treatment of reopened or infected surgical wound
7.3
13.5
22
36
SPAT1148
SPAT
Treatment of chronic ulcer or burn
5.1
12.8
33
84
T84.5
ICD-10 Finland
Infection and inflammatory reaction due to internal joint prosthesis
30.5
12.4
16
6
J01MA12
ATC
levofloxacin; systemic
4.2
12.2
46
157
Y83.9
ICD-10 Finland
Surgical procedure, unspecified as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
13.2
12.1
21
19
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
11.4
81
420
TPH04
NOMESCO Finland
Cathetrisation of vein
3.9
11.3
49
183
X59
ICD-10 Finland
Exposure to unspecified factor
4.0
11.3
43
147
WX408
NOMESCO Finland
General anesthesy, balanced
3.8
11.1
51
198
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
24.3
11.0
15
7
WX704
NOMESCO Finland
Intubation
5.5
10.5
23
50
JN3AD
NOMESCO Finland
Abdominal CT examination
4.4
10.2
31
89
TQW11
NOMESCO Finland
Vacuum treatment of wound
44.1
10.2
12
*
J01FF01
ATC
clindamycin; systemic
3.4
9.4
52
224
QDB05
NOMESCO Finland
Revision of wound of skin of lower limb
14.1
9.2
15
12
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
4.2
8.9
28
82
J01CF05
ATC
flucloxacillin; systemic
5.0
8.8
21
49
WX882
NOMESCO Finland
High dependency care
18.1
8.8
13
8
WX320
NOMESCO Finland
Spinalanesthesy
3.3
8.7
49
211
Y88.3
ICD-10 Finland
Sequelae of surgical and medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
12.1
8.6
15
14
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.4
8.6
42
166
Y62.8
ICD-10 Finland
Failure of sterile precautions during surgical and medical care during other surgical and medical care
+∞
8.4
8
*
AWB00
NOMESCO Finland
Reoperation for superficial infection in surgery of the nervous system
+∞
8.4
8
*
B01AB05
ATC
enoxaparin; parenteral
3.1
8.4
58
281
J01DB01
ATC
cefalexin; oral
6.4
8.3
110
833
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.0
7.8
25
74
TPH07
NOMESCO Finland
Cathetrisation of artery
4.0
7.8
25
74
L28
ICPC
Limited function/disability (L)
3.2
7.6
39
157
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.6
7.5
30
103
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
12.0
7.5
13
12
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.3
7.4
34
128
Y83.8
ICD-10 Finland
Other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
9.8
7.3
14
16
Y83.1
ICD-10 Finland
Surgical operation with implant of artificial internal device as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
32.2
7.3
9
*
J01XX08
ATC
linezolid; systemic
32.2
7.3
9
*
N06AX21
ATC
duloxetine; oral
4.0
7.1
23
68
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.3
7.1
33
125
WX725
NOMESCO Finland
Noninvasive ventilation
4.8
7.0
17
40
N02AX02
ATC
tramadol; systemic, rectal
2.8
7.0
67
377
SPAT1211
SPAT
Application of soft bandage
4.3
7.0
20
54
NF3AA
NOMESCO Finland
Femur X-ray examination
12.0
7.0
12
11
NF1AA
NOMESCO Finland
Hip X-ray examination
4.1
7.0
21
59
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.6
6.9
26
86
T84.0
ICD-10 Finland
Mechanical complication of internal joint prosthesis
9.6
6.8
13
15
S18
ICPC
Laceration/cut
2.8
6.8
74
444
ZXD05
NOMESCO Finland
Urgent procedure
2.8
6.7
48
231
T81.3
ICD-10 Finland
Disruption of operation wound, not elsewhere classified
11.0
6.7
12
12
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.9
6.7
22
66
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.6
6.5
25
83
I50.9
ICD-10 Finland
Heart failure, unspecified
3.3
6.3
27
97
N02AJ06
ATC
codeine and paracetamol; systemic
2.7
6.2
68
402
T81.8
ICD-10 Finland
Other complications of procedures, not elsewhere classified
13.5
6.2
10
8
C03CA01
ATC
furosemide; systemic
2.7
6.2
47
232
N02AA05
ATC
oxycodone; systemic
2.9
6.2
37
161
I50.0
ICD-10 Finland
Congestive heart failure
4.5
6.1
16
40
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
7.1
6.1
14
22
M48.0
ICD-10 Finland
Spinal stenosis
3.3
6.1
26
93
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
6.1e-01
1.2e+00
2.9e+00
5.7e+00
3.9e+00
1.6e+00
1.2e+00
cases:64.10%
controls:49.15%
cases:62.39%
controls:33.42%
cases:53.85%
controls:6.07%
cases:57.26%
controls:0.43%
cases:75.86%
controls:6.25%
cases:71.96%
controls:34.41%
cases:87.95%
controls:68.67%
75
575
42
595
73
391
44
779
63
71
54
1099
67
5
50
1165
88
73
28
1095
77
385
30
734
73
607
10
277
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
9.4e-01
2.1e+00
3.2e+00
—
2.7e+00
2.7e+00
2.0e+00
cases:20.51%
controls:9.15%
cases:13.68%
controls:1.97%
cases:9.40%
controls:0.43%
—
—
cases:6.90%
controls:0.51%
cases:17.76%
controls:1.43%
cases:21.69%
controls:3.51%
24
107
93
1063
16
23
101
1147
11
5
106
1165
—
8
6
108
1162
19
16
88
1103
18
31
65
853
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
3.5e-01
9.3e-01
2.5e+00
5.4e+00
3.1e+00
1.7e+00
2.1e+00
cases:74.36%
controls:67.09%
cases:78.63%
controls:59.23%
cases:63.25%
controls:12.56%
cases:53.85%
controls:0.51%
cases:74.14%
controls:11.82%
cases:89.72%
controls:62.02%
cases:98.80%
controls:90.72%
87
785
30
385
92
693
25
477
74
147
43
1023
63
6
54
1164
86
138
30
1030
96
694
11
425
82
802
1
82
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
3.6e-01
9.0e-01
2.5e+00
5.4e+00
3.1e+00
1.7e+00
2.1e+00
cases:74.36%
controls:66.84%
cases:77.78%
controls:58.63%
cases:63.25%
controls:12.48%
cases:53.85%
controls:0.51%
cases:74.14%
controls:11.64%
cases:89.72%
controls:62.11%
cases:98.80%
controls:90.61%
87
782
30
388
91
686
26
484
74
146
43
1024
63
6
54
1164
86
136
30
1032
96
695
11
424
82
801
1
83
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
3.6e-01
8.9e-01
2.5e+00
5.4e+00
3.1e+00
1.7e+00
2.1e+00
cases:74.36%
controls:66.92%
cases:77.78%
controls:58.89%
cases:63.25%
controls:12.48%
cases:53.85%
controls:0.51%
cases:74.14%
controls:11.64%
cases:89.72%
controls:62.02%
cases:98.80%
controls:90.61%
87
783
30
387
91
689
26
481
74
146
43
1024
63
6
54
1164
86
136
30
1032
96
694
11
425
82
801
1
83
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
3.6e-01
9.0e-01
2.5e+00
5.4e+00
3.1e+00
1.7e+00
2.1e+00
cases:74.36%
controls:66.92%
cases:77.78%
controls:58.72%
cases:63.25%
controls:12.48%
cases:53.85%
controls:0.51%
cases:74.14%
controls:11.64%
cases:89.72%
controls:62.29%
cases:98.80%
controls:90.72%
87
783
30
387
91
687
26
483
74
146
43
1024
63
6
54
1164
86
136
30
1032
96
697
11
422
82
802
1
82
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
3.6e-01
8.9e-01
2.5e+00
5.4e+00
3.1e+00
1.7e+00
2.1e+00
cases:74.36%
controls:66.92%
cases:77.78%
controls:58.89%
cases:63.25%
controls:12.48%
cases:53.85%
controls:0.51%
cases:74.14%
controls:11.64%
cases:89.72%
controls:62.20%
cases:98.80%
controls:90.84%
87
783
30
387
91
689
26
481
74
146
43
1024
63
6
54
1164
86
136
30
1032
96
696
11
423
82
803
1
81
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
3.6e-01
8.9e-01
2.5e+00
5.4e+00
3.1e+00
1.7e+00
2.1e+00
cases:74.36%
controls:66.92%
cases:77.78%
controls:58.89%
cases:63.25%
controls:12.48%
cases:53.85%
controls:0.51%
cases:74.14%
controls:11.73%
cases:89.72%
controls:62.20%
cases:98.80%
controls:90.72%
87
783
30
387
91
689
26
481
74
146
43
1024
63
6
54
1164
86
137
30
1031
96
696
11
423
82
802
1
82
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
3.6e-01
9.0e-01
2.5e+00
5.4e+00
3.1e+00
1.5e+00
2.1e+00
cases:74.36%
controls:66.84%
cases:77.78%
controls:58.72%
cases:63.25%
controls:12.48%
cases:53.85%
controls:0.51%
cases:74.14%
controls:11.64%
cases:87.85%
controls:62.02%
cases:98.80%
controls:90.61%
87
782
30
388
91
687
26
483
74
146
43
1024
63
6
54
1164
86
136
30
1032
94
694
13
425
82
801
1
83
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
4.1e-01
1.1e+00
2.5e+00
5.1e+00
2.8e+00
1.8e+00
1.3e+00
cases:82.05%
controls:75.13%
cases:88.03%
controls:71.45%
cases:78.63%
controls:23.16%
cases:64.10%
controls:1.03%
cases:81.03%
controls:21.40%
cases:94.39%
controls:74.44%
cases:98.80%
controls:95.70%
96
879
21
291
103
836
14
334
92
271
25
899
75
12
42
1158
94
250
22
918
101
833
6
286
82
846
1
38
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
4.3e-01
1.0e+00
2.7e+00
5.1e+00
3.0e+00
1.3e+00
1.0e+00
cases:66.67%
controls:56.50%
cases:70.94%
controls:47.09%
cases:58.12%
controls:8.38%
cases:42.74%
controls:0.43%
cases:64.66%
controls:8.22%
cases:77.57%
controls:49.15%
cases:91.57%
controls:79.98%
78
661
39
509
83
551
34
619
68
98
49
1072
50
5
67
1165
75
96
41
1072
83
550
24
569
76
707
7
177
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
4.7e-01
1.0e+00
2.7e+00
5.1e+00
3.0e+00
1.2e+00
1.1e+00
cases:67.52%
controls:56.50%
cases:70.94%
controls:47.26%
cases:58.12%
controls:8.55%
cases:42.74%
controls:0.43%
cases:63.79%
controls:8.39%
cases:77.57%
controls:50.13%
cases:92.77%
controls:80.66%
79
661
38
509
83
553
34
617
68
100
49
1070
50
5
67
1165
74
98
42
1070
83
561
24
558
77
713
6
171
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
7.6e-01
2.0e+00
4.0e+00
1.0e+50
3.1e+00
2.1e+00
1.5e+00
cases:11.97%
controls:5.98%
cases:17.09%
controls:2.65%
cases:22.22%
controls:0.51%
cases:7.69%
controls:0.00%
cases:10.34%
controls:0.51%
cases:17.76%
controls:2.59%
cases:28.92%
controls:8.71%
14
70
103
1100
20
31
97
1139
26
6
91
1164
9
0
108
1170
12
6
104
1162
19
29
88
1090
24
77
59
807
Outpatient Hospital
22 [8756]
22 [8756]
7.7e-01
1.6e+00
4.2e+00
1.0e+50
2.8e+00
1.7e+00
1.5e+00
cases:43.59%
controls:26.41%
cases:25.64%
controls:6.67%
cases:35.90%
controls:0.85%
cases:19.66%
controls:0.00%
cases:12.07%
controls:0.86%
cases:17.76%
controls:3.84%
cases:25.30%
controls:6.79%
51
309
66
861
30
78
87
1092
42
10
75
1160
23
0
94
1170
14
10
102
1158
19
43
88
1076
21
60
62
824
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
4.0e-01
1.0e+00
2.6e+00
4.9e+00
2.7e+00
1.3e+00
1.1e+00
cases:70.09%
controls:61.03%
cases:75.21%
controls:52.31%
cases:58.97%
controls:10.09%
cases:44.44%
controls:0.60%
cases:63.79%
controls:11.04%
cases:83.18%
controls:56.57%
cases:95.18%
controls:86.76%
82
714
35
456
88
612
29
558
69
118
48
1052
52
7
65
1163
74
129
42
1039
89
633
18
486
79
767
4
117
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
6.0e-01
1.8e+00
4.6e+00
1.0e+50
3.1e+00
1.6e+00
1.3e+00
cases:23.93%
controls:14.70%
cases:31.62%
controls:6.92%
cases:36.75%
controls:0.60%
cases:12.82%
controls:0.00%
cases:18.10%
controls:0.94%
cases:24.30%
controls:6.08%
cases:45.78%
controls:19.12%
28
172
89
998
37
81
80
1089
43
7
74
1163
15
0
102
1170
21
11
95
1157
26
68
81
1051
38
169
45
715
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
5.7e-01
1.7e+00
4.3e+00
1.0e+50
3.2e+00
1.6e+00
1.5e+00
cases:15.38%
controls:9.32%
cases:20.51%
controls:4.53%
cases:28.21%
controls:0.51%
cases:8.55%
controls:0.00%
cases:14.66%
controls:0.68%
cases:17.76%
controls:4.20%
cases:36.14%
controls:11.09%
18
109
99
1061
24
53
93
1117
33
6
84
1164
10
0
107
1170
17
8
99
1160
19
47
88
1072
30
98
53
786
Inpatient Hospital
21 [8717]
21 [8717]
7.0e-01
1.3e+00
4.2e+00
1.0e+50
3.4e+00
1.2e+00
1.4e+00
cases:47.01%
controls:30.68%
cases:26.50%
controls:8.72%
cases:36.75%
controls:0.85%
cases:38.46%
controls:0.00%
cases:21.55%
controls:0.94%
cases:18.69%
controls:6.52%
cases:28.92%
controls:9.39%
55
359
62
811
31
102
86
1068
43
10
74
1160
45
0
72
1170
25
11
91
1157
20
73
87
1046
24
83
59
801
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
4.4e-01
1.8e+00
3.8e+00
1.0e+50
3.4e+00
1.5e+00
1.4e+00
cases:10.26%
controls:6.84%
cases:18.80%
controls:3.59%
cases:20.51%
controls:0.60%
cases:19.66%
controls:0.00%
cases:21.55%
controls:0.94%
cases:15.89%
controls:4.20%
cases:36.14%
controls:12.44%
12
80
105
1090
22
42
95
1128
24
7
93
1163
23
0
94
1170
25
11
91
1157
17
47
90
1072
30
110
53
774
Emergency Room Visit
ER [9203]
ER [9203]
9.9e-01
1.5e+00
3.4e+00
—
2.8e+00
1.5e+00
1.3e+00
cases:62.39%
controls:38.21%
cases:35.90%
controls:11.37%
cases:29.91%
controls:1.45%
—
—
cases:15.52%
controls:1.11%
cases:33.64%
controls:10.37%
cases:50.60%
controls:22.17%
73
447
44
723
42
133
75
1037
35
17
82
1153
—
18
13
98
1155
36
116
71
1003
42
196
41
688
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
T81.4 [45575538]
2.1e+00
3.2e+00
1.0e+50
1.0e+50
—
3.6e+00
2.3e+00
cases:8.55%
controls:1.11%
cases:9.40%
controls:0.43%
cases:15.38%
controls:0.00%
cases:67.52%
controls:0.00%
—
—
cases:19.63%
controls:0.63%
cases:9.64%
controls:1.02%
10
13
107
1157
11
5
106
1165
18
0
99
1170
79
0
38
1170
—
21
7
86
1112
8
9
75
875
General Practice
1 [38004446]
1 [38004446]
1.1e+00
1.4e+00
2.9e+00
1.0e+50
3.1e+00
1.2e+00
9.3e-01
cases:35.04%
controls:15.81%
cases:19.66%
controls:5.47%
cases:11.11%
controls:0.68%
cases:20.51%
controls:0.00%
cases:16.38%
controls:0.86%
cases:19.63%
controls:6.79%
cases:36.14%
controls:18.33%
41
185
76
985
23
64
94
1106
13
8
104
1162
24
0
93
1170
19
10
97
1158
21
76
86
1043
30
162
53
722
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
7.9e-01
1.5e+00
1.6e+00
3.7e+00
1.7e+00
1.7e+00
1.0e+50
cases:97.44%
controls:94.53%
cases:96.58%
controls:86.50%
cases:73.50%
controls:35.13%
cases:42.74%
controls:1.79%
cases:75.86%
controls:37.24%
cases:97.20%
controls:86.77%
cases:100.00%
controls:98.87%
114
1106
3
64
113
1012
4
158
86
411
31
759
50
21
67
1149
88
435
28
733
104
971
3
148
83
874
0
10
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
1.0e+00
1.5e+00
3.6e+00
1.0e+50
2.3e+00
1.3e+00
8.5e-01
cases:32.48%
controls:14.62%
cases:18.80%
controls:4.87%
cases:15.38%
controls:0.51%
cases:6.84%
controls:0.00%
cases:4.31%
controls:0.43%
cases:13.08%
controls:4.02%
cases:26.51%
controls:13.35%
38
171
79
999
22
57
95
1113
18
6
99
1164
8
0
109
1170
5
5
111
1163
14
45
93
1074
22
118
61
766
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
5.2e-01
1.3e+00
2.8e+00
1.0e+50
3.2e+00
1.2e+00
1.2e+00
cases:20.51%
controls:13.25%
cases:17.09%
controls:5.47%
cases:12.82%
controls:0.85%
cases:4.27%
controls:0.00%
cases:9.48%
controls:0.43%
cases:14.95%
controls:5.09%
cases:32.53%
controls:12.78%
24
155
93
1015
20
64
97
1106
15
10
102
1160
5
0
112
1170
11
5
105
1163
16
57
91
1062
27
113
56
771
Orthopedic Surgery
20 [38004465]
20 [38004465]
7.5e-01
1.6e+00
2.8e+00
—
3.1e+00
1.4e+00
6.1e-01
cases:33.33%
controls:19.15%
cases:28.21%
controls:7.35%
cases:19.66%
controls:1.45%
—
—
cases:19.83%
controls:1.11%
cases:27.10%
controls:8.40%
cases:32.53%
controls:20.81%
39
224
78
946
33
86
84
1084
23
17
94
1153
—
23
13
93
1155
29
94
78
1025
27
184
56
700
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
1.9e-01
7.3e-01
2.1e+00
4.0e+00
2.0e+00
7.0e-01
3.6e-01
cases:44.44%
controls:39.83%
cases:52.99%
controls:35.13%
cases:35.90%
controls:6.50%
cases:22.22%
controls:0.51%
cases:37.07%
controls:7.28%
cases:56.07%
controls:38.87%
cases:79.52%
controls:72.96%
52
466
65
704
62
411
55
759
42
76
75
1094
26
6
91
1164
43
85
73
1083
60
435
47
684
66
645
17
239
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
6.9e-01
1.5e+00
3.2e+00
1.0e+50
2.5e+00
1.2e+00
1.1e+00
cases:32.48%
controls:19.40%
cases:30.77%
controls:9.32%
cases:28.21%
controls:1.54%
cases:11.97%
controls:0.00%
cases:12.07%
controls:1.11%
cases:28.04%
controls:10.55%
cases:57.83%
controls:31.22%
38
227
79
943
36
109
81
1061
33
18
84
1152
14
0
103
1170
14
13
102
1155
30
118
77
1001
48
276
35
608
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
9.8e-01
9.9e-01
3.1e+00
—
2.5e+00
1.5e+00
1.4e+00
cases:21.37%
controls:9.23%
cases:6.84%
controls:2.65%
cases:8.55%
controls:0.43%
—
—
cases:5.17%
controls:0.43%
cases:11.21%
controls:2.77%
cases:16.87%
controls:4.86%
25
108
92
1062
8
31
109
1139
10
5
107
1165
—
6
5
110
1163
12
31
95
1088
14
43
69
841
Internal Medicine
11 [38004456]
11 [38004456]
9.5e-01
1.2e+00
2.9e+00
—
2.2e+00
1.1e+00
9.7e-01
cases:39.32%
controls:20.00%
cases:21.37%
controls:7.61%
cases:15.38%
controls:1.03%
—
—
cases:7.76%
controls:0.94%
cases:19.63%
controls:7.60%
cases:33.73%
controls:16.18%
46
234
71
936
25
89
92
1081
18
12
99
1158
—
9
11
107
1157
21
85
86
1034
28
143
55
741
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
7.2e-01
1.0e+00
2.2e+00
—
2.7e+00
1.8e+00
1.3e+00
cases:29.06%
controls:16.67%
cases:27.35%
controls:11.79%
cases:17.09%
controls:2.14%
—
—
cases:22.41%
controls:1.88%
cases:40.19%
controls:10.10%
cases:59.04%
controls:27.26%
34
195
83
975
32
138
85
1032
20
25
97
1145
—
26
22
90
1146
43
113
64
1006
49
241
34
643
Emergency Medicine
93 [38004510]
93 [38004510]
7.7e-01
1.3e+00
2.8e+00
—
2.8e+00
1.4e+00
7.3e-01
cases:39.32%
controls:22.99%
cases:30.77%
controls:10.77%
cases:22.22%
controls:1.71%
—
—
cases:17.24%
controls:1.28%
cases:36.45%
controls:11.89%
cases:56.63%
controls:38.57%
46
269
71
901
36
126
81
1044
26
20
91
1150
—
20
15
96
1153
39
133
68
986
47
341
36
543
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
1.7e+00
2.5e+00
—
—
3.1e+00
1.7e+00
1.1e+00
cases:11.11%
controls:2.14%
cases:10.26%
controls:0.94%
—
—
—
—
cases:8.62%
controls:0.43%
cases:9.35%
controls:1.79%
cases:13.25%
controls:4.98%
13
25
104
1145
12
11
105
1159
—
—
10
5
106
1163
10
20
97
1099
11
44
72
840
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
8.2e-01
1.3e+00
3.3e+00
1.0e+50
3.5e+00
7.3e-01
9.7e-01
cases:12.82%
controls:6.07%
cases:11.97%
controls:3.59%
cases:13.68%
controls:0.60%
cases:18.80%
controls:0.00%
cases:12.07%
controls:0.43%
cases:9.35%
controls:4.74%
cases:39.76%
controls:20.02%
15
71
102
1099
14
42
103
1128
16
7
101
1163
22
0
95
1170
14
5
102
1163
10
53
97
1066
33
177
50
707
Inpatient Visit
IP [9201]
IP [9201]
6.3e-01
9.3e-01
4.2e+00
—
2.6e+00
1.1e+00
9.7e-01
cases:12.82%
controls:7.26%
cases:11.11%
controls:4.70%
cases:22.22%
controls:0.43%
—
—
cases:7.76%
controls:0.60%
cases:13.08%
controls:4.74%
cases:34.94%
controls:16.97%
15
85
102
1085
13
55
104
1115
26
5
91
1165
—
9
7
107
1161
14
53
93
1066
29
150
54
734
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
7.9e-01
9.4e-01
2.6e+00
—
2.5e+00
1.2e+00
8.4e-01
cases:40.17%
controls:23.42%
cases:29.91%
controls:14.27%
cases:18.80%
controls:1.71%
—
—
cases:18.97%
controls:1.97%
cases:37.38%
controls:14.83%
cases:55.42%
controls:34.95%
47
274
70
896
35
167
82
1003
22
20
95
1150
—
22
23
94
1145
40
166
67
953
46
309
37
575
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
5.8e-01
8.2e-01
2.1e+00
—
2.6e+00
1.6e+00
1.3e+00
cases:44.44%
controls:30.94%
cases:39.32%
controls:22.14%
cases:24.79%
controls:3.93%
—
—
cases:34.48%
controls:3.94%
cases:57.94%
controls:21.54%
cases:77.11%
controls:47.85%
52
362
65
808
46
259
71
911
29
46
88
1124
—
40
46
76
1122
62
241
45
878
64
423
19
461
Outpatient Visit
OP [9202]
OP [9202]
1.2e+00
9.2e-01
2.1e+00
2.7e+00
1.7e+00
9.2e-01
-3.6e-01
cases:94.87%
controls:84.36%
cases:82.91%
controls:65.81%
cases:55.56%
controls:13.50%
cases:5.98%
controls:0.43%
cases:45.69%
controls:13.61%
cases:81.31%
controls:63.45%
cases:90.36%
controls:93.10%
111
987
6
183
97
770
20
400
65
158
52
1012
7
5
110
1165
53
159
63
1009
87
710
20
409
75
823
8
61
Neurosurgery
14 [38004459]
14 [38004459]
1.0e+00
2.4e+00
3.4e+00
1.0e+50
—
2.5e+00
9.8e-01
cases:8.55%
controls:3.33%
cases:14.53%
controls:1.54%
cases:11.11%
controls:0.43%
cases:7.69%
controls:0.00%
—
—
cases:13.08%
controls:1.25%
cases:7.23%
controls:2.83%
10
39
107
1131
17
18
100
1152
13
5
104
1165
9
0
108
1170
—
14
14
93
1105
6
25
77
859
Medical Oncology
90 [38004507]
90 [38004507]
6.7e-01
1.0e+00
1.9e+00
—
2.7e+00
1.5e+00
1.1e+00
cases:9.40%
controls:5.04%
cases:12.82%
controls:4.96%
cases:5.98%
controls:0.94%
—
—
cases:11.21%
controls:0.86%
cases:13.08%
controls:3.40%
cases:16.87%
controls:6.33%
11
59
106
1111
15
58
102
1112
7
11
110
1159
—
13
10
103
1158
14
38
93
1081
14
56
69
828
General Surgery
2 [38004447]
2 [38004447]
1.0e+00
2.0e+00
3.4e+00
1.0e+50
—
1.6e+00
3.6e-01
cases:28.21%
controls:12.48%
cases:19.66%
controls:3.08%
cases:11.11%
controls:0.43%
cases:7.69%
controls:0.00%
—
—
cases:11.21%
controls:2.59%
cases:10.84%
controls:7.81%
33
146
84
1024
23
36
94
1134
13
5
104
1165
9
0
108
1170
—
12
29
95
1090
9
69
74
815
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
6.3e-01
1.1e+00
2.8e+00
1.0e+50
2.9e+00
1.1e+00
6.3e-01
cases:44.44%
controls:29.91%
cases:22.22%
controls:8.97%
cases:15.38%
controls:1.11%
cases:13.68%
controls:0.00%
cases:20.69%
controls:1.37%
cases:20.56%
controls:7.95%
cases:37.35%
controls:24.10%
52
350
65
820
26
105
91
1065
18
13
99
1157
16
0
101
1170
24
16
92
1152
22
89
85
1030
31
213
52
671
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
1.4e+00
2.6e+00
—
1.0e+50
—
2.3e+00
1.6e+00
cases:14.53%
controls:4.10%
cases:17.95%
controls:1.62%
—
—
cases:11.97%
controls:0.00%
—
—
cases:10.28%
controls:1.16%
cases:25.30%
controls:6.56%
17
48
100
1122
21
19
96
1151
—
14
0
103
1170
—
11
13
96
1106
21
58
62
826
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
6.2e-01
1.2e+00
2.2e+00
—
2.0e+00
1.1e+00
1.2e+00
cases:23.08%
controls:13.93%
cases:25.64%
controls:9.23%
cases:14.53%
controls:1.88%
—
—
cases:14.66%
controls:2.31%
cases:21.50%
controls:8.22%
cases:48.19%
controls:21.61%
27
163
90
1007
30
108
87
1062
17
22
100
1148
—
17
27
99
1141
23
92
84
1027
40
191
43
693
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
5.4e-01
1.2e+00
2.2e+00
—
1.9e+00
1.1e+00
1.1e+00
cases:26.50%
controls:17.35%
cases:29.06%
controls:10.68%
cases:28.21%
controls:4.02%
—
—
cases:23.28%
controls:4.20%
cases:27.10%
controls:10.90%
cases:50.60%
controls:24.66%
31
203
86
967
34
125
83
1045
33
47
84
1123
—
27
49
89
1119
29
122
78
997
42
218
41
666
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
8.2e-01
1.1e+00
1.5e+00
1.5e+00
2.2e+00
1.4e+00
1.0e+00
cases:17.09%
controls:8.29%
cases:12.82%
controls:4.79%
cases:7.69%
controls:1.79%
cases:4.27%
controls:0.94%
cases:14.66%
controls:1.80%
cases:20.56%
controls:6.08%
cases:32.53%
controls:14.48%
20
97
97
1073
15
56
102
1114
9
21
108
1149
5
11
112
1159
17
21
99
1147
22
68
85
1051
27
128
56
756
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-3.9e-01
-1.3e-01
1.9e+00
—
—
2.3e+00
2.9e+00
cases:21.37%
controls:28.63%
cases:10.26%
controls:11.54%
cases:8.55%
controls:1.37%
—
—
—
—
cases:9.35%
controls:0.98%
cases:37.35%
controls:3.05%
25
335
92
835
12
135
105
1035
10
16
107
1154
—
—
10
11
97
1108
31
27
52
857
EKG study
11524-6 [3013512]
11524-6 [3013512]
4.1e-01
1.4e+00
3.5e+00
—
1.2e+00
1.0e+00
1.1e+00
cases:15.38%
controls:10.77%
cases:19.66%
controls:5.73%
cases:14.53%
controls:0.51%
—
—
cases:4.31%
controls:1.28%
cases:16.82%
controls:6.61%
cases:43.37%
controls:20.36%
18
126
99
1044
23
67
94
1103
17
6
100
1164
—
5
15
111
1153
18
74
89
1045
36
180
47
704
Atrial fibrillation and flutter
I48 [45596206]
I48 [45596206]
8.4e-01
1.3e+00
2.4e+00
1.0e+50
1.9e+00
1.4e+00
8.6e-01
cases:15.38%
controls:7.26%
cases:13.68%
controls:4.19%
cases:6.84%
controls:0.68%
cases:4.27%
controls:0.00%
cases:6.90%
controls:1.11%
cases:14.02%
controls:3.84%
cases:16.87%
controls:7.92%
18
85
99
1085
16
49
101
1121
8
8
109
1162
5
0
112
1170
8
13
108
1155
15
43
92
1076
14
70
69
814
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
4.5e-01
7.9e-01
2.7e+00
1.0e+50
2.2e+00
1.0e+00
9.8e-01
cases:19.66%
controls:13.50%
cases:11.11%
controls:5.38%
cases:11.11%
controls:0.85%
cases:5.13%
controls:0.00%
cases:6.03%
controls:0.68%
cases:15.89%
controls:6.34%
cases:40.96%
controls:20.59%
23
158
94
1012
13
63
104
1107
13
10
104
1160
6
0
111
1170
7
8
109
1160
17
71
90
1048
34
182
49
702
Disease/condition unspecnature/site
A99 [2002000232]
A99 [2002000232]
2.0e+00
2.7e+00
—
—
1.0e+50
2.2e+00
1.1e+00
cases:9.40%
controls:1.37%
cases:6.84%
controls:0.51%
—
—
—
—
cases:6.90%
controls:0.00%
cases:7.48%
controls:0.89%
cases:9.64%
controls:3.28%
11
16
106
1154
8
6
109
1164
—
—
8
0
108
1168
8
10
99
1109
8
29
75
855
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
1.0e+00
1.3e+00
3.0e+00
—
—
1.5e+00
7.1e-01
cases:23.08%
controls:9.57%
cases:11.11%
controls:3.42%
cases:11.11%
controls:0.60%
—
—
—
—
cases:13.08%
controls:3.22%
cases:14.46%
controls:7.69%
27
112
90
1058
13
40
104
1130
13
7
104
1163
—
—
14
36
93
1083
12
68
71
816
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
4.2e-01
5.5e-01
2.6e+00
—
2.1e+00
1.0e+00
8.4e-01
cases:20.51%
controls:14.44%
cases:13.68%
controls:8.38%
cases:15.38%
controls:1.37%
—
—
cases:9.48%
controls:1.28%
cases:20.56%
controls:8.67%
cases:43.37%
controls:24.77%
24
169
93
1001
16
98
101
1072
18
16
99
1154
—
11
15
105
1153
22
97
85
1022
36
219
47
665
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
5.0e-01
4.2e-01
2.3e+00
—
2.1e+00
9.6e-01
1.1e+00
cases:23.93%
controls:15.98%
cases:14.53%
controls:10.09%
cases:14.53%
controls:1.62%
—
—
cases:12.07%
controls:1.71%
cases:22.43%
controls:10.01%
cases:54.22%
controls:28.39%
28
187
89
983
17
118
100
1052
17
19
100
1151
—
14
20
102
1148
24
112
83
1007
45
251
38
633
Atherosclerosis of arteries of extremities
I70.2 [45538421]
I70.2 [45538421]
1.3e+00
2.1e+00
—
1.0e+50
—
2.7e+00
1.6e+00
cases:6.84%
controls:1.88%
cases:6.84%
controls:0.85%
—
—
cases:5.13%
controls:0.00%
—
—
cases:9.35%
controls:0.71%
cases:9.64%
controls:2.04%
8
22
109
1148
8
10
109
1160
—
6
0
111
1170
—
10
8
97
1111
8
18
75
866
Vascular Surgery
77 [38004496]
77 [38004496]
8.8e-01
1.8e+00
—
1.0e+50
2.5e+00
2.0e+00
4.6e-01
cases:10.26%
controls:4.53%
cases:11.11%
controls:1.97%
—
—
cases:5.98%
controls:0.00%
cases:5.17%
controls:0.43%
cases:10.28%
controls:1.52%
cases:9.64%
controls:6.33%
12
53
105
1117
13
23
104
1147
—
7
0
110
1170
6
5
110
1163
11
17
96
1102
8
56
75
828
Cardiology
6 [38004451]
6 [38004451]
7.4e-01
1.5e+00
2.6e+00
—
2.2e+00
8.8e-01
6.0e-01
cases:26.50%
controls:14.62%
cases:21.37%
controls:5.98%
cases:11.97%
controls:1.03%
—
—
cases:6.03%
controls:0.68%
cases:14.95%
controls:6.79%
cases:30.12%
controls:19.12%
31
171
86
999
25
70
92
1100
14
12
103
1158
—
7
8
109
1160
16
76
91
1043
25
169
58
715
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
2.7e-01
6.2e-01
2.6e+00
—
2.8e+00
8.6e-01
4.2e-01
cases:62.39%
controls:55.90%
cases:54.70%
controls:39.40%
cases:47.86%
controls:6.67%
—
—
cases:50.00%
controls:5.82%
cases:62.62%
controls:41.47%
cases:80.72%
controls:73.30%
73
654
44
516
64
461
53
709
56
78
61
1092
—
58
68
58
1100
67
464
40
655
67
648
16
236
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
7.3e-01
1.2e+00
2.8e+00
—
2.1e+00
1.1e+00
6.6e-01
cases:16.24%
controls:8.55%
cases:16.24%
controls:5.30%
cases:12.82%
controls:0.85%
—
—
cases:5.17%
controls:0.68%
cases:11.21%
controls:3.84%
cases:19.28%
controls:10.97%
19
100
98
1070
19
62
98
1108
15
10
102
1160
—
6
8
110
1160
12
43
95
1076
16
97
67
787
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
2.9e-01
8.7e-01
1.7e+00
2.2e+00
2.2e+00
1.2e+00
1.2e+00
cases:64.96%
controls:58.12%
cases:66.67%
controls:45.47%
cases:31.62%
controls:7.78%
cases:4.27%
controls:0.51%
cases:43.97%
controls:7.79%
cases:76.64%
controls:49.51%
cases:93.98%
controls:82.81%
76
680
41
490
78
532
39
638
37
91
80
1079
5
6
112
1164
51
91
65
1077
82
554
25
565
78
732
5
152
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
5.0e-01
6.9e-01
2.5e+00
—
2.3e+00
1.2e+00
7.0e-01
cases:18.80%
controls:12.31%
cases:11.97%
controls:6.41%
cases:8.55%
controls:0.77%
—
—
cases:7.76%
controls:0.86%
cases:17.76%
controls:5.99%
cases:28.92%
controls:16.74%
22
144
95
1026
14
75
103
1095
10
9
107
1161
—
9
10
107
1158
19
67
88
1052
24
148
59
736
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
5.7e-01
9.7e-01
1.7e+00
—
2.4e+00
8.7e-01
7.0e-01
cases:31.62%
controls:20.68%
cases:32.48%
controls:15.47%
cases:16.24%
controls:3.59%
—
—
cases:25.86%
controls:3.00%
cases:28.97%
controls:14.66%
cases:49.40%
controls:32.58%
37
242
80
928
38
181
79
989
19
42
98
1128
—
30
35
86
1133
31
164
76
955
41
288
42
596
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
2.0e+00
2.2e+00
—
—
—
1.5e+00
1.7e+00
cases:10.26%
controls:1.45%
cases:7.69%
controls:0.94%
—
—
—
—
—
—
cases:4.67%
controls:1.07%
cases:16.87%
controls:3.62%
12
17
105
1153
9
11
108
1159
—
—
—
5
12
102
1107
14
32
69
852
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
3.5e-01
6.6e-01
2.0e+00
—
1.7e+00
9.9e-01
1.0e+00
cases:35.04%
controls:27.52%
cases:25.64%
controls:15.13%
cases:11.11%
controls:1.62%
—
—
cases:12.93%
controls:2.57%
cases:34.58%
controls:16.44%
cases:61.45%
controls:36.76%
41
322
76
848
30
177
87
993
13
19
104
1151
—
15
30
101
1138
37
184
70
935
51
325
32
559
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
8.0e-01
1.1e+00
2.2e+00
—
1.6e+00
4.0e-01
7.1e-01
cases:43.59%
controls:25.73%
cases:30.77%
controls:13.42%
cases:15.38%
controls:2.05%
—
—
cases:10.34%
controls:2.31%
cases:19.63%
controls:14.12%
cases:51.81%
controls:34.50%
51
301
66
869
36
157
81
1013
18
24
99
1146
—
12
27
104
1141
21
158
86
961
43
305
40
579
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
4.3e-01
7.3e-01
2.8e+00
—
—
1.5e+00
1.2e+00
cases:12.82%
controls:8.72%
cases:10.26%
controls:5.21%
cases:6.84%
controls:0.43%
—
—
—
—
cases:17.76%
controls:4.65%
cases:34.94%
controls:13.46%
15
102
102
1068
12
61
105
1109
8
5
109
1165
—
—
19
52
88
1067
29
119
54
765
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
5.8e-01
8.3e-01
1.6e+00
—
1.9e+00
1.0e+00
6.0e-01
cases:42.74%
controls:29.57%
cases:33.33%
controls:17.95%
cases:11.97%
controls:2.74%
—
—
cases:12.93%
controls:2.14%
cases:38.32%
controls:18.14%
cases:59.04%
controls:44.23%
50
346
67
824
39
210
78
960
14
32
103
1138
—
15
25
101
1143
41
203
66
916
49
391
34
493
Laceration/cut
S18 [2002000983]
S18 [2002000983]
7.6e-01
8.6e-01
—
—
3.3e+00
1.2e+00
4.1e-01
cases:27.35%
controls:14.96%
cases:11.11%
controls:5.04%
—
—
—
—
cases:19.83%
controls:0.86%
cases:14.02%
controls:4.65%
cases:21.69%
controls:15.50%
32
175
85
995
13
59
104
1111
—
—
23
10
93
1158
15
52
92
1067
18
137
65
747
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
6.8e-01
1.0e+00
2.7e+00
—
1.9e+00
1.1e+00
1.4e+00
cases:15.38%
controls:8.46%
cases:10.26%
controls:3.93%
cases:8.55%
controls:0.60%
—
—
cases:5.17%
controls:0.77%
cases:14.95%
controls:5.54%
cases:46.99%
controls:17.31%
18
99
99
1071
12
46
105
1124
10
7
107
1163
—
6
9
110
1159
16
62
91
1057
39
153
44
731
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
8.7e-01
1.4e+00
1.7e+00
—
—
1.0e+00
1.0e+00
cases:16.24%
controls:7.52%
cases:18.80%
controls:5.47%
cases:8.55%
controls:1.62%
—
—
—
—
cases:16.82%
controls:6.70%
cases:30.12%
controls:13.46%
19
88
98
1082
22
64
95
1106
10
19
107
1151
—
—
18
75
89
1044
25
119
58
765
Obstetrics / Gynecology
16 [38004461]
16 [38004461]
6.1e-01
8.6e-01
2.6e+00
1.0e+50
2.5e+00
6.3e-01
1.5e-01
cases:17.95%
controls:10.60%
cases:10.26%
controls:4.62%
cases:8.55%
controls:0.68%
cases:6.84%
controls:0.00%
cases:6.03%
controls:0.51%
cases:8.41%
controls:4.65%
cases:14.46%
controls:12.67%
21
124
96
1046
12
54
105
1116
10
8
107
1162
8
0
109
1170
7
6
109
1162
9
52
98
1067
12
112
71
772
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
5.4e-01
7.4e-01
2.3e+00
—
1.7e+00
1.1e+00
-9.3e-02
cases:14.53%
controls:8.97%
cases:11.97%
controls:6.07%
cases:7.69%
controls:0.85%
—
—
cases:6.90%
controls:1.37%
cases:15.89%
controls:5.72%
cases:16.87%
controls:18.21%
17
105
100
1065
14
71
103
1099
9
10
108
1160
—
8
16
108
1152
17
64
90
1055
14
161
69
723
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
5.1e-01
8.4e-01
1.3e+00
—
2.5e+00
8.6e-01
8.1e-01
cases:25.64%
controls:17.18%
cases:23.08%
controls:11.45%
cases:8.55%
controls:2.39%
—
—
cases:21.55%
controls:2.14%
cases:22.43%
controls:10.90%
cases:46.99%
controls:28.28%
30
201
87
969
27
134
90
1036
10
28
107
1142
—
25
25
91
1143
24
122
83
997
39
250
44
634
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
1.0e+50
1.3e+00
1.8e+00
2.3e+00
9.6e-01
2.2e+00
1.0e+50
cases:100.00%
controls:98.12%
cases:97.44%
controls:91.28%
cases:88.03%
controls:55.81%
cases:20.51%
controls:2.48%
cases:77.59%
controls:57.02%
cases:99.07%
controls:91.96%
cases:100.00%
controls:97.85%
117
1148
0
22
114
1068
3
102
103
653
14
517
24
29
93
1141
90
666
26
502
106
1029
1
90
83
865
0
19
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
1.2e+00
2.0e+00
—
—
—
1.8e+00
1.2e+00
cases:11.11%
controls:3.59%
cases:6.84%
controls:0.94%
—
—
—
—
—
—
cases:7.48%
controls:1.34%
cases:7.23%
controls:2.38%
13
42
104
1128
8
11
109
1159
—
—
—
8
15
99
1104
6
21
77
863
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
1.2e+00
1.9e+00
—
—
—
1.8e+00
1.2e+00
cases:11.11%
controls:3.68%
cases:8.55%
controls:1.37%
—
—
—
—
—
—
cases:7.48%
controls:1.25%
cases:12.05%
controls:3.96%
13
43
104
1127
10
16
107
1154
—
—
—
8
14
99
1105
10
35
73
849
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
4.7e-01
9.2e-01
1.4e+00
—
2.6e+00
8.2e-01
7.9e-01
cases:23.93%
controls:16.41%
cases:23.93%
controls:11.11%
cases:8.55%
controls:2.22%
—
—
cases:19.83%
controls:1.80%
cases:20.56%
controls:10.28%
cases:42.17%
controls:24.89%
28
192
89
978
28
130
89
1040
10
26
107
1144
—
23
21
93
1147
22
115
85
1004
35
220
48
664
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
4.5e-01
9.1e-01
1.5e+00
—
2.5e+00
6.5e-01
7.0e-01
cases:24.79%
controls:17.44%
cases:24.79%
controls:11.71%
cases:9.40%
controls:2.22%
—
—
cases:19.83%
controls:1.97%
cases:19.63%
controls:11.35%
cases:40.96%
controls:25.57%
29
204
88
966
29
137
88
1033
11
26
106
1144
—
23
23
93
1145
21
127
86
992
34
226
49
658
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
4.6e-01
8.6e-01
1.4e+00
—
2.6e+00
7.3e-01
7.1e-01
cases:23.93%
controls:16.58%
cases:23.08%
controls:11.28%
cases:8.55%
controls:2.22%
—
—
cases:19.83%
controls:1.80%
cases:19.63%
controls:10.55%
cases:39.76%
controls:24.43%
28
194
89
976
27
132
90
1038
10
26
107
1144
—
23
21
93
1147
21
118
86
1001
33
216
50
668
Clinic/Center
261Q00000X [38004207]
261Q00000X [38004207]
1.7e+00
2.5e+00
—
—
—
—
2.3e+00
cases:5.13%
controls:0.94%
cases:5.13%
controls:0.43%
—
—
—
—
—
—
—
—
cases:8.43%
controls:0.90%
6
11
111
1159
6
5
111
1165
—
—
—
—
7
8
76
876
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
7.1e-01
1.7e+00
—
—
—
1.9e+00
1.2e+00
cases:4.27%
controls:2.14%
cases:7.69%
controls:1.45%
—
—
—
—
—
—
cases:7.48%
controls:1.16%
cases:15.66%
controls:5.54%
5
25
112
1145
9
17
108
1153
—
—
—
8
13
99
1106
13
49
70
835
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
1.7e-01
4.1e-01
1.5e+00
—
2.4e+00
1.0e+00
1.2e+00
cases:28.21%
controls:24.87%
cases:17.09%
controls:12.05%
cases:6.84%
controls:1.62%
—
—
cases:10.34%
controls:1.03%
cases:29.91%
controls:13.14%
cases:61.45%
controls:31.79%
33
291
84
879
20
141
97
1029
8
19
109
1151
—
12
12
104
1156
32
147
75
972
51
281
32
603
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
1.1e+00
1.2e+00
2.2e+00
—
—
1.2e+00
1.4e+00
cases:17.09%
controls:6.58%
cases:10.26%
controls:3.25%
cases:8.55%
controls:1.03%
—
—
—
—
cases:9.35%
controls:3.04%
cases:18.07%
controls:5.20%
20
77
97
1093
12
38
105
1132
10
12
107
1158
—
—
10
34
97
1085
15
46
68
838
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
5.9e-01
9.2e-01
1.6e+00
—
2.9e+00
9.5e-01
8.7e-01
cases:17.95%
controls:10.85%
cases:17.09%
controls:7.61%
cases:6.84%
controls:1.45%
—
—
cases:16.38%
controls:1.11%
cases:15.89%
controls:6.79%
cases:32.53%
controls:16.86%
21
127
96
1043
20
89
97
1081
8
17
109
1153
—
19
13
97
1155
17
76
90
1043
27
149
56
735
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
2.3e-01
5.2e-01
2.2e+00
—
2.3e+00
5.8e-01
-2.2e-01
cases:55.56%
controls:49.74%
cases:53.85%
controls:40.85%
cases:45.30%
controls:8.12%
—
—
cases:47.41%
controls:8.22%
cases:57.94%
controls:43.43%
cases:61.45%
controls:66.40%
65
582
52
588
63
478
54
692
53
95
64
1075
—
55
96
61
1072
62
486
45
633
51
587
32
297
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
9.1e-01
2.2e+00
—
1.0e+50
—
2.3e+00
6.4e-01
cases:11.11%
controls:4.79%
cases:8.55%
controls:1.03%
—
—
cases:11.97%
controls:0.00%
—
—
cases:12.15%
controls:1.34%
cases:8.43%
controls:4.64%
13
56
104
1114
10
12
107
1158
—
14
0
103
1170
—
13
15
94
1104
7
41
76
843
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
30313-1 [3002173]
—
2.1e+00
—
—
—
2.4e+00
1.2e+00
—
—
cases:7.69%
controls:1.03%
—
—
—
—
—
—
cases:7.48%
controls:0.71%
cases:13.25%
controls:4.30%
—
9
12
108
1158
—
—
—
8
8
99
1111
11
38
72
846
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
9.1e-01
1.0e+00
2.5e+00
—
—
6.1e-01
1.1e+00
cases:22.22%
controls:10.34%
cases:11.11%
controls:4.27%
cases:6.84%
controls:0.60%
—
—
—
—
cases:8.41%
controls:4.74%
cases:28.92%
controls:12.22%
26
121
91
1049
13
50
104
1120
8
7
109
1163
—
—
9
53
98
1066
24
108
59
776
nortriptyline; oral, parenteral
N06AA10 [21604697]
N06AA10 [21604697]
2.1e+00
2.3e+00
—
—
—
—
1.6e+00
cases:5.13%
controls:0.68%
cases:4.27%
controls:0.43%
—
—
—
—
—
—
—
—
cases:6.02%
controls:1.24%
6
8
111
1162
5
5
112
1165
—
—
—
—
5
11
78
873
Leukocytes [#/volume] in Synovial fluid
26469-7 [3000475]
26469-7 [3000475]
2.3e+00
—
—
—
—
—
2.0e+00
cases:4.27%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:1.02%
5
5
112
1165
—
—
—
—
—
6
9
77
875
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
8.0e-01
1.5e+00
2.0e+00
—
—
9.1e-01
4.8e-01
cases:36.75%
controls:20.68%
cases:22.22%
controls:5.90%
cases:8.55%
controls:1.20%
—
—
—
—
cases:14.95%
controls:6.61%
cases:24.10%
controls:16.40%
43
242
74
928
26
69
91
1101
10
14
107
1156
—
—
16
74
91
1045
20
145
63
739
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
4.6e-01
9.3e-01
1.3e+00
—
2.6e+00
8.0e-01
8.1e-01
cases:23.93%
controls:16.58%
cases:23.93%
controls:11.03%
cases:7.69%
controls:2.22%
—
—
cases:19.83%
controls:1.80%
cases:20.56%
controls:10.46%
cases:42.17%
controls:24.55%
28
194
89
976
28
129
89
1041
9
26
108
1144
—
23
21
93
1147
22
117
85
1002
35
217
48
667
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
4.4e-01
1.7e+00
—
—
2.5e+00
—
3.5e-01
cases:10.26%
controls:6.84%
cases:7.69%
controls:1.45%
—
—
—
—
cases:6.03%
controls:0.51%
—
—
cases:8.43%
controls:6.11%
12
80
105
1090
9
17
108
1153
—
—
7
6
109
1162
—
7
54
76
830
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
6.0e-02
4.4e-01
2.0e+00
—
2.2e+00
4.4e-01
-3.6e-01
cases:42.74%
controls:41.28%
cases:45.30%
controls:34.79%
cases:37.61%
controls:7.78%
—
—
cases:41.38%
controls:7.02%
cases:46.73%
controls:36.01%
cases:57.83%
controls:66.18%
50
483
67
687
53
407
64
763
44
91
73
1079
—
48
82
68
1086
50
403
57
716
48
585
35
299
Oxygen saturation in Arterial blood
2708-6 [3016502]
2708-6 [3016502]
8.4e-01
1.9e+00
—
—
—
2.3e+00
1.0e+00
cases:4.27%
controls:1.88%
cases:6.84%
controls:1.11%
—
—
—
—
—
—
cases:7.48%
controls:0.80%
cases:13.25%
controls:5.09%
5
22
112
1148
8
13
109
1157
—
—
—
8
9
99
1110
11
45
72
839
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
QDB10 [2001309970]
1.7e+00
—
—
—
—
2.4e+00
—
cases:6.84%
controls:1.28%
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.45%
—
—
8
15
109
1155
—
—
—
—
5
5
102
1114
—
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
4.7e-01
8.7e-01
1.3e+00
—
2.4e+00
7.6e-01
8.3e-01
cases:26.50%
controls:18.38%
cases:24.79%
controls:12.14%
cases:8.55%
controls:2.56%
—
—
cases:20.69%
controls:2.31%
cases:22.43%
controls:11.89%
cases:48.19%
controls:28.96%
31
215
86
955
29
142
88
1028
10
30
107
1140
—
24
27
92
1141
24
133
83
986
40
256
43
628
Respiratory and circulatory monitoring
WX700 [2001310817]
WX700 [2001310817]
1.6e+00
2.5e+00
—
1.0e+50
1.0e+50
—
1.2e+00
cases:11.97%
controls:2.74%
cases:6.84%
controls:0.60%
—
—
cases:5.13%
controls:0.00%
cases:4.31%
controls:0.00%
—
—
cases:8.43%
controls:2.71%
14
32
103
1138
8
7
109
1163
—
6
0
111
1170
5
0
111
1168
—
7
24
76
860
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
5.6e-01
8.6e-01
1.3e+00
—
2.4e+00
8.4e-01
8.3e-01
cases:26.50%
controls:17.09%
cases:23.93%
controls:11.71%
cases:8.55%
controls:2.48%
—
—
cases:18.97%
controls:2.14%
cases:22.43%
controls:11.08%
cases:43.37%
controls:25.00%
31
200
86
970
28
137
89
1033
10
29
107
1141
—
22
25
94
1143
24
124
83
995
36
221
47
663
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
W01 [45756243]
7.2e-01
1.6e+00
—
—
2.4e+00
7.2e-01
6.9e-01
cases:11.11%
controls:5.73%
cases:7.69%
controls:1.71%
—
—
—
—
cases:6.03%
controls:0.60%
cases:4.67%
controls:2.32%
cases:14.46%
controls:7.81%
13
67
104
1103
9
20
108
1150
—
—
7
7
109
1161
5
26
102
1093
12
69
71
815
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
4.3e-01
7.8e-01
2.1e+00
—
1.7e+00
6.8e-01
6.0e-01
cases:41.03%
controls:31.20%
cases:22.22%
controls:11.62%
cases:12.82%
controls:1.79%
—
—
cases:7.76%
controls:1.46%
cases:18.69%
controls:10.46%
cases:43.37%
controls:29.64%
48
365
69
805
26
136
91
1034
15
21
102
1149
—
9
17
107
1151
20
117
87
1002
36
262
47
622
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
-5.9e-02
3.8e-01
2.4e+00
—
1.3e+00
3.7e-02
-8.1e-02
cases:31.62%
controls:32.91%
cases:23.93%
controls:17.69%
cases:17.95%
controls:1.97%
—
—
cases:9.48%
controls:2.65%
cases:18.69%
controls:18.14%
cases:38.55%
controls:40.50%
37
385
80
785
28
207
89
963
21
23
96
1147
—
11
31
105
1137
20
203
87
916
32
358
51
526
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
6.7e-01
1.8e+00
—
—
—
1.9e+00
1.1e+00
cases:4.27%
controls:2.22%
cases:7.69%
controls:1.37%
—
—
—
—
—
—
cases:7.48%
controls:1.16%
cases:14.46%
controls:5.32%
5
26
112
1144
9
16
108
1154
—
—
—
8
13
99
1106
12
47
71
837
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
6.7e-01
1.8e+00
—
—
—
1.9e+00
1.1e+00
cases:4.27%
controls:2.22%
cases:7.69%
controls:1.37%
—
—
—
—
—
—
cases:7.48%
controls:1.16%
cases:14.46%
controls:5.32%
5
26
112
1144
9
16
108
1154
—
—
—
8
13
99
1106
12
47
71
837
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
SPAT1306 [2001700407]
1.1e+00
2.1e+00
—
—
—
—
1.6e+00
cases:6.84%
controls:2.48%
cases:5.13%
controls:0.68%
—
—
—
—
—
—
—
—
cases:9.64%
controls:2.04%
8
29
109
1141
6
8
111
1162
—
—
—
—
8
18
75
866
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
8.1e-01
1.3e+00
2.3e+00
—
—
1.3e+00
2.4e-01
cases:6.84%
controls:3.16%
cases:9.40%
controls:2.65%
cases:5.13%
controls:0.51%
—
—
—
—
cases:8.41%
controls:2.50%
cases:12.05%
controls:9.73%
8
37
109
1133
11
31
106
1139
6
6
111
1164
—
—
9
28
98
1091
10
86
73
798
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
4.2e-01
6.2e-01
2.5e+00
—
1.5e+00
1.2e+00
2.1e-01
cases:16.24%
controls:11.28%
cases:11.97%
controls:6.84%
cases:9.40%
controls:0.85%
—
—
cases:6.03%
controls:1.37%
cases:18.69%
controls:6.52%
cases:22.89%
controls:19.46%
19
132
98
1038
14
80
103
1090
11
10
106
1160
—
7
16
109
1152
20
73
87
1046
19
172
64
712
Pulmonary Disease
29 [38004472]
29 [38004472]
5.3e-01
8.7e-01
1.8e+00
—
1.9e+00
6.5e-01
5.3e-01
cases:17.95%
controls:11.37%
cases:11.97%
controls:5.38%
cases:5.98%
controls:1.03%
—
—
cases:8.62%
controls:1.46%
cases:11.21%
controls:6.17%
cases:22.89%
controls:14.93%
21
133
96
1037
14
63
103
1107
7
12
110
1158
—
10
17
106
1151
12
69
95
1050
19
132
64
752
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
6.7e-01
1.7e+00
—
—
—
1.9e+00
1.1e+00
cases:4.27%
controls:2.22%
cases:7.69%
controls:1.45%
—
—
—
—
—
—
cases:7.48%
controls:1.16%
cases:14.46%
controls:5.43%
5
26
112
1144
9
17
108
1153
—
—
—
8
13
99
1106
12
48
71
836
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5810-7 [3019150]
6.0e-01
6.0e-01
—
—
2.4e+00
1.3e+00
4.1e-01
cases:14.53%
controls:8.55%
cases:8.55%
controls:4.87%
—
—
—
—
cases:6.90%
controls:0.68%
cases:16.82%
controls:5.45%
cases:19.28%
controls:13.69%
17
100
100
1070
10
57
107
1113
—
—
8
8
108
1160
18
61
89
1058
16
121
67
763
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
1.3e+00
2.3e+00
—
1.0e+50
—
—
7.9e-01
cases:12.82%
controls:3.76%
cases:11.97%
controls:1.37%
—
—
cases:5.98%
controls:0.00%
—
—
—
—
cases:10.84%
controls:5.20%
15
44
102
1126
14
16
103
1154
—
7
0
110
1170
—
—
9
46
74
838
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
1.4e+00
1.8e+00
—
—
—
2.2e+00
1.3e+00
cases:10.26%
controls:2.65%
cases:5.13%
controls:0.85%
—
—
—
—
—
—
cases:6.54%
controls:0.80%
cases:10.84%
controls:3.05%
12
31
105
1139
6
10
111
1160
—
—
—
7
9
100
1110
9
27
74
857
Infectious Disease
44 [38004484]
44 [38004484]
9.5e-01
—
—
—
—
2.1e+00
1.4e+00
cases:5.98%
controls:2.39%
—
—
—
—
—
—
—
—
cases:8.41%
controls:1.07%
cases:14.46%
controls:3.85%
7
28
110
1142
—
—
—
—
9
12
98
1107
12
34
71
850
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
5.4e-01
6.6e-01
1.7e+00
—
1.0e+00
8.8e-01
1.0e+00
cases:35.04%
controls:23.93%
cases:24.79%
controls:14.62%
cases:10.26%
controls:2.14%
—
—
cases:9.48%
controls:3.60%
cases:28.97%
controls:14.48%
cases:51.81%
controls:27.71%
41
280
76
890
29
171
88
999
12
25
105
1145
—
11
42
105
1126
31
162
76
957
43
245
40
639
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
8.0e-01
7.9e-01
2.3e+00
—
—
8.9e-01
1.2e+00
cases:8.55%
controls:4.02%
cases:5.13%
controls:2.39%
cases:5.13%
controls:0.51%
—
—
—
—
cases:4.67%
controls:1.97%
cases:18.07%
controls:6.45%
10
47
107
1123
6
28
111
1142
6
6
111
1164
—
—
5
22
102
1097
15
57
68
827
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
1.5e+00
—
—
—
—
2.0e+00
1.4e+00
cases:12.82%
controls:3.16%
—
—
—
—
—
—
—
—
cases:8.41%
controls:1.25%
cases:8.43%
controls:2.26%
15
37
102
1133
—
—
—
—
9
14
98
1105
7
20
76
864
Neurology
13 [38004458]
13 [38004458]
8.8e-01
9.7e-01
—
—
1.9e+00
1.4e+00
1.0e+00
cases:25.64%
controls:12.56%
cases:11.11%
controls:4.53%
—
—
—
—
cases:4.31%
controls:0.68%
cases:17.76%
controls:4.92%
cases:24.10%
controls:10.29%
30
147
87
1023
13
53
104
1117
—
—
5
8
111
1160
19
55
88
1064
20
91
63
793
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
6.0e-01
5.6e-01
2.3e+00
—
9.8e-01
9.8e-01
8.5e-01
cases:65.81%
controls:51.45%
cases:42.74%
controls:29.83%
cases:35.04%
controls:4.96%
—
—
cases:13.79%
controls:5.65%
cases:53.27%
controls:30.03%
cases:73.49%
controls:54.30%
77
602
40
568
50
349
67
821
41
58
76
1112
—
16
66
100
1102
57
336
50
783
61
480
22
404
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
N02AE01 [21604287]
1.5e+00
1.8e+00
—
—
—
1.2e+00
5.0e-01
cases:14.53%
controls:3.76%
cases:5.98%
controls:1.03%
—
—
—
—
—
—
cases:5.61%
controls:1.79%
cases:7.23%
controls:4.52%
17
44
100
1126
7
12
110
1158
—
—
—
6
20
101
1099
6
40
77
844
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
5.9e-01
1.6e+00
—
—
—
—
1.5e+00
cases:5.98%
controls:3.42%
cases:7.69%
controls:1.62%
—
—
—
—
—
—
—
—
cases:20.48%
controls:5.32%
7
40
110
1130
9
19
108
1151
—
—
—
—
17
47
66
837
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
7.2e-02
1.2e+00
2.0e+00
—
1.9e+00
6.5e-01
2.6e-01
cases:9.40%
controls:8.80%
cases:13.68%
controls:4.36%
cases:4.27%
controls:0.60%
—
—
cases:6.90%
controls:1.11%
cases:9.35%
controls:5.09%
cases:20.48%
controls:16.63%
11
103
106
1067
16
51
101
1119
5
7
112
1163
—
8
13
108
1155
10
57
97
1062
17
147
66
737
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
14731-4 [3019309]
8.8e-01
8.2e-01
—
—
—
1.6e+00
1.5e+00
cases:14.53%
controls:6.58%
cases:5.98%
controls:2.74%
—
—
—
—
—
—
cases:8.41%
controls:1.88%
cases:22.89%
controls:6.00%
17
77
100
1093
7
32
110
1138
—
—
—
9
21
98
1098
19
53
64
831
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
5.9e-01
1.5e+00
3.1e+00
—
—
1.1e+00
5.6e-01
cases:17.09%
controls:10.26%
cases:7.69%
controls:1.88%
cases:8.55%
controls:0.43%
—
—
—
—
cases:5.61%
controls:1.97%
cases:12.05%
controls:7.24%
20
120
97
1050
9
22
108
1148
10
5
107
1165
—
—
6
22
101
1097
10
64
73
820
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
5.0e-01
6.2e-01
2.1e+00
—
1.6e+00
9.7e-01
-5.4e-02
cases:15.38%
controls:9.91%
cases:12.82%
controls:7.35%
cases:7.69%
controls:1.03%
—
—
cases:6.03%
controls:1.28%
cases:16.82%
controls:7.15%
cases:20.48%
controls:21.38%
18
116
99
1054
15
86
102
1084
9
12
108
1158
—
7
15
109
1153
18
80
89
1039
17
189
66
695
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
SPAT1223 [2001700324]
7.2e-01
1.2e+00
—
—
—
1.4e+00
1.6e+00
cases:16.24%
controls:8.63%
cases:5.98%
controls:1.79%
—
—
—
—
—
—
cases:13.08%
controls:3.57%
cases:27.71%
controls:7.24%
19
101
98
1069
7
21
110
1149
—
—
—
14
40
93
1079
23
64
60
820
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
1.7e-01
8.0e-01
2.7e+00
—
-1.0e+50
4.1e-01
2.7e-01
cases:16.24%
controls:14.10%
cases:13.68%
controls:6.67%
cases:9.40%
controls:0.68%
—
—
cases:0.00%
controls:0.68%
cases:7.48%
controls:5.09%
cases:20.48%
controls:16.40%
19
165
98
1005
16
78
101
1092
11
8
106
1162
—
0
8
116
1160
8
57
99
1062
17
145
66
739
No procedures
SPAT1301 [2001700402]
SPAT1301 [2001700402]
5.9e-01
8.4e-01
—
—
2.7e+00
9.8e-01
8.0e-01
cases:16.24%
controls:9.74%
cases:6.84%
controls:3.08%
—
—
—
—
cases:6.03%
controls:0.43%
cases:7.48%
controls:2.95%
cases:16.87%
controls:8.37%
19
114
98
1056
8
36
109
1134
—
—
7
5
109
1163
8
33
99
1086
14
74
69
810
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
59275-8 [40762366]
—
2.7e+00
—
—
—
—
1.3e+00
—
—
cases:6.84%
controls:0.51%
—
—
—
—
—
—
—
—
cases:8.43%
controls:2.49%
—
8
6
109
1164
—
—
—
—
7
22
76
862
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
FB1BD [2001302407]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:0.57%
—
—
—
—
—
—
6
5
77
879
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
SPAT1220 [2001700321]
-1.0e+50
—
—
—
—
—
2.6e+00
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:1.02%
0
13
117
1157
—
—
—
—
—
10
9
73
875
Gas panel - Arterial blood
24336-0 [3019060]
24336-0 [3019060]
—
—
—
—
—
2.6e+00
7.3e-01
—
—
—
—
—
—
—
—
—
—
cases:5.61%
controls:0.45%
cases:7.23%
controls:3.62%
—
—
—
—
—
6
5
101
1114
6
32
77
852
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
8.5e-01
1.2e+00
2.5e+00
—
—
1.4e+00
9.4e-02
cases:5.98%
controls:2.65%
cases:7.69%
controls:2.56%
cases:5.13%
controls:0.43%
—
—
—
—
cases:9.35%
controls:2.59%
cases:12.05%
controls:11.09%
7
31
110
1139
9
30
108
1140
6
5
111
1165
—
—
10
29
97
1090
10
98
73
786
Aortic (valve) stenosis
I35.0 [45576869]
I35.0 [45576869]
—
1.5e+00
2.5e+00
—
—
1.4e+00
9.7e-01
—
—
cases:5.13%
controls:1.20%
cases:5.13%
controls:0.43%
—
—
—
—
cases:4.67%
controls:1.16%
cases:6.02%
controls:2.38%
—
6
14
111
1156
6
5
111
1165
—
—
5
13
102
1106
5
21
78
863
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
5.0e-01
7.9e-01
1.3e+00
—
2.5e+00
8.1e-01
7.1e-01
cases:25.64%
controls:17.26%
cases:22.22%
controls:11.45%
cases:8.55%
controls:2.39%
—
—
cases:21.55%
controls:2.14%
cases:21.50%
controls:10.90%
cases:44.58%
controls:28.28%
30
202
87
968
26
134
91
1036
10
28
107
1142
—
25
25
91
1143
23
122
84
997
37
250
46
634
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
5.2e-01
7.9e-01
1.2e+00
—
2.5e+00
8.0e-01
7.0e-01
cases:27.35%
controls:18.29%
cases:23.08%
controls:11.97%
cases:8.55%
controls:2.65%
—
—
cases:21.55%
controls:2.14%
cases:22.43%
controls:11.53%
cases:45.78%
controls:29.64%
32
214
85
956
27
140
90
1030
10
31
107
1139
—
25
25
91
1143
24
129
83
990
38
262
45
622
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
M51.1 [45562747]
—
2.5e+00
—
—
—
—
—
—
—
cases:5.98%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
7
6
110
1164
—
—
—
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
4.9e-01
4.2e-01
1.4e+00
—
1.5e+00
9.1e-01
1.9e-01
cases:24.79%
controls:16.84%
cases:14.53%
controls:10.09%
cases:5.13%
controls:1.37%
—
—
cases:7.76%
controls:1.80%
cases:24.30%
controls:11.44%
cases:34.94%
controls:30.66%
29
197
88
973
17
118
100
1052
6
16
111
1154
—
9
21
107
1147
26
128
81
991
29
271
54
613
Initiation and monitoring of IV fluid therapy
SPAT1083 [2001700184]
SPAT1083 [2001700184]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:0.68%
—
—
—
—
—
—
6
6
77
878
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
OMOP4821991 [45756751]
1.4e+00
—
—
—
—
—
2.4e+00
cases:4.27%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.57%
5
13
112
1157
—
—
—
—
—
5
5
78
879
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
4.6e-01
3.9e-01
1.5e+00
—
1.5e+00
8.9e-01
2.6e-01
cases:25.64%
controls:17.95%
cases:14.53%
controls:10.34%
cases:5.98%
controls:1.45%
—
—
cases:7.76%
controls:1.80%
cases:24.30%
controls:11.62%
cases:37.35%
controls:31.56%
30
210
87
960
17
121
100
1049
7
17
110
1153
—
9
21
107
1147
26
130
81
989
31
279
52
605
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
1.1e+00
1.3e+00
—
—
—
1.0e+00
6.7e-01
cases:12.82%
controls:4.87%
cases:10.26%
controls:2.91%
—
—
—
—
—
—
cases:7.48%
controls:2.86%
cases:16.87%
controls:9.39%
15
57
102
1113
12
34
105
1136
—
—
—
8
32
99
1087
14
83
69
801
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
Z00.4 [45605094]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.45%
—
—
—
—
—
—
—
5
5
102
1114
—
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
3.3e-01
7.9e-01
1.3e+00
—
1.3e+00
1.1e+00
1.2e+00
cases:11.97%
controls:8.89%
cases:11.97%
controls:5.81%
cases:4.27%
controls:1.20%
—
—
cases:5.17%
controls:1.46%
cases:14.02%
controls:4.92%
cases:20.48%
controls:7.01%
14
104
103
1066
14
68
103
1102
5
14
112
1156
—
6
17
110
1151
15
55
92
1064
17
62
66
822
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
76080-1 [46235759]
—
—
—
—
—
-1.0e+50
2.4e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
cases:10.84%
controls:1.13%
—
—
—
—
—
0
6
107
1113
9
10
74
874
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
40988-8 [3044254]
—
—
—
—
—
-1.0e+50
2.4e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
cases:10.84%
controls:1.13%
—
—
—
—
—
0
6
107
1113
9
10
74
874
Sleep apnoea
G47.3 [45562094]
G47.3 [45562094]
6.3e-01
1.0e+00
2.3e+00
—
1.6e+00
8.3e-01
3.2e-01
cases:11.97%
controls:6.75%
cases:10.26%
controls:3.93%
cases:5.13%
controls:0.51%
—
—
cases:4.31%
controls:0.94%
cases:9.35%
controls:4.29%
cases:12.05%
controls:9.05%
14
79
103
1091
12
46
105
1124
6
6
111
1164
—
5
11
111
1157
10
48
97
1071
10
80
73
804
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
E11.9 [45561952]
2.2e-01
2.3e-01
2.3e+00
—
—
7.0e-01
6.9e-01
cases:10.26%
controls:8.38%
cases:5.13%
controls:4.10%
cases:4.27%
controls:0.43%
—
—
—
—
cases:8.41%
controls:4.38%
cases:18.07%
controls:9.95%
12
98
105
1072
6
48
111
1122
5
5
112
1165
—
—
9
49
98
1070
15
88
68
796
Sampling
SPAT1263 [2001700364]
SPAT1263 [2001700364]
4.9e-01
4.6e-01
—
—
2.3e+00
4.1e-01
8.4e-01
cases:21.37%
controls:14.27%
cases:9.40%
controls:6.15%
—
—
—
—
cases:6.90%
controls:0.77%
cases:8.41%
controls:5.72%
cases:25.30%
controls:12.78%
25
167
92
1003
11
72
106
1098
—
—
8
9
108
1159
9
64
98
1055
21
113
62
771
Nursing episode
950 [44777714]
950 [44777714]
4.3e-01
—
—
—
2.2e+00
—
9.8e-01
cases:4.27%
controls:2.82%
—
—
—
—
—
—
cases:5.17%
controls:0.60%
—
—
cases:9.64%
controls:3.85%
5
33
112
1137
—
—
—
6
7
110
1161
—
8
34
75
850
Intensive care
WX872 [2001310844]
WX872 [2001310844]
2.2e+00
—
—
—
—
—
—
cases:5.13%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
111
1163
—
—
—
—
—
—
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
1.2e+00
—
2.2e+00
—
—
1.1e+00
1.1e+00
cases:6.84%
controls:2.14%
—
—
cases:5.13%
controls:0.60%
—
—
—
—
cases:4.67%
controls:1.61%
cases:12.05%
controls:4.52%
8
25
109
1145
—
6
7
111
1163
—
—
5
18
102
1101
10
40
73
844
Dry eye syndrome
H04.10 [2000502254]
H04.10 [2000502254]
1.1e+00
2.2e+00
—
—
—
2.0e+00
—
cases:5.13%
controls:1.71%
cases:5.13%
controls:0.60%
—
—
—
—
—
—
cases:5.61%
controls:0.80%
—
—
6
20
111
1150
6
7
111
1163
—
—
—
6
9
101
1110
—
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
SPAT1148 [2001700249]
8.5e-01
1.4e+00
—
—
—
2.2e+00
1.3e+00
cases:5.98%
controls:2.65%
cases:4.27%
controls:1.11%
—
—
—
—
—
—
cases:7.48%
controls:0.89%
cases:9.64%
controls:2.71%
7
31
110
1139
5
13
112
1157
—
—
—
8
10
99
1109
8
24
75
860
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
2524-7 [3014111]
8.9e-01
2.1e+00
—
—
—
—
9.2e-01
cases:4.27%
controls:1.79%
cases:6.84%
controls:0.85%
—
—
—
—
—
—
—
—
cases:9.64%
controls:4.07%
5
21
112
1149
8
10
109
1160
—
—
—
—
8
36
75
848
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
1.2e+00
1.6e+00
—
—
—
2.1e+00
6.7e-01
cases:4.27%
controls:1.28%
cases:5.13%
controls:1.03%
—
—
—
—
—
—
cases:5.61%
controls:0.71%
cases:6.02%
controls:3.17%
5
15
112
1155
6
12
111
1158
—
—
—
6
8
101
1111
5
28
78
856
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
4.9e-01
7.1e-01
2.1e+00
—
1.3e+00
8.7e-01
-1.6e-01
cases:11.97%
controls:7.69%
cases:10.26%
controls:5.30%
cases:5.98%
controls:0.77%
—
—
cases:4.31%
controls:1.20%
cases:11.21%
controls:5.00%
cases:13.25%
controls:15.16%
14
90
103
1080
12
62
105
1108
7
9
110
1161
—
5
14
111
1154
12
56
95
1063
11
134
72
750
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
4.8e-01
6.8e-01
2.1e+00
—
1.4e+00
1.0e+00
-8.4e-02
cases:11.97%
controls:7.78%
cases:10.26%
controls:5.47%
cases:5.98%
controls:0.77%
—
—
cases:4.31%
controls:1.11%
cases:12.15%
controls:4.83%
cases:13.25%
controls:14.25%
14
91
103
1079
12
64
105
1106
7
9
110
1161
—
5
13
111
1155
13
54
94
1065
11
126
72
758
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
19231-0 [3004490]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:1.47%
—
—
—
—
—
—
9
13
74
871
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
1.5e-01
2.1e+00
—
—
—
1.7e+00
2.8e-01
cases:5.13%
controls:4.44%
cases:7.69%
controls:1.03%
—
—
—
—
—
—
cases:6.54%
controls:1.25%
cases:6.02%
controls:4.64%
6
52
111
1118
9
12
108
1158
—
—
—
7
14
100
1105
5
41
78
843
Digoxin [Moles/volume] in Serum or Plasma
14698-5 [3027456]
14698-5 [3027456]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:1.13%
—
—
—
—
—
—
7
10
76
874
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
2639-3 [3005895]
—
1.7e+00
—
—
—
—
2.1e+00
—
—
cases:4.27%
controls:0.77%
—
—
—
—
—
—
—
—
cases:8.43%
controls:1.13%
—
5
9
112
1161
—
—
—
—
7
10
76
874
Acute suppurative otitis media
H66.0 [45572040]
H66.0 [45572040]
2.1e+00
—
—
—
—
—
—
cases:5.13%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
111
1162
—
—
—
—
—
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
1.1e+00
8.6e-01
—
—
—
8.3e-01
9.0e-01
cases:15.38%
controls:5.56%
cases:10.26%
controls:4.62%
—
—
—
—
—
—
cases:10.28%
controls:4.74%
cases:27.71%
controls:13.46%
18
65
99
1105
12
54
105
1116
—
—
—
11
53
96
1066
23
119
60
765
desonide
D07AB08 [21602112]
D07AB08 [21602112]
4.9e-01
2.2e+00
—
—
—
—
2.0e+00
cases:4.27%
controls:2.65%
cases:4.27%
controls:0.51%
—
—
—
—
—
—
—
—
cases:7.23%
controls:1.02%
5
31
112
1139
5
6
112
1164
—
—
—
—
6
9
77
875
Intubation
WX704 [2001310820]
WX704 [2001310820]
1.2e+00
—
—
—
—
—
2.0e+00
cases:5.13%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:1.02%
6
18
111
1152
—
—
—
—
—
6
9
77
875
Monitoring of emergency patient
SPAT1104 [2001700205]
SPAT1104 [2001700205]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:1.02%
—
—
—
—
—
—
6
9
77
875
Application of soft bandage
SPAT1211 [2001700312]
SPAT1211 [2001700312]
1.1e+00
—
—
—
1.0e+50
-1.0e+50
2.0e+00
cases:4.27%
controls:1.45%
—
—
—
—
—
—
cases:4.31%
controls:0.00%
cases:0.00%
controls:0.45%
cases:8.43%
controls:1.24%
5
17
112
1153
—
—
—
5
0
111
1168
0
5
107
1114
7
11
76
873
Heart failure, unspecified
I50.9 [45576879]
I50.9 [45576879]
1.1e+00
2.0e+00
—
—
—
1.5e+00
1.1e+00
cases:5.98%
controls:2.05%
cases:8.55%
controls:1.28%
—
—
—
—
—
—
cases:5.61%
controls:1.25%
cases:12.05%
controls:4.41%
7
24
110
1146
10
15
107
1155
—
—
—
6
14
101
1105
10
39
73
845
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
4.1e-01
2.7e-01
2.0e+00
—
1.9e+00
6.2e-01
5.4e-01
cases:20.51%
controls:14.62%
cases:10.26%
controls:8.03%
cases:6.84%
controls:1.03%
—
—
cases:5.17%
controls:0.77%
cases:14.95%
controls:8.67%
cases:46.99%
controls:34.05%
24
171
93
999
12
94
105
1076
8
12
109
1158
—
6
9
110
1159
16
97
91
1022
39
301
44
583
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
4.7e-01
1.9e+00
—
—
—
—
—
cases:11.97%
controls:7.86%
cases:12.82%
controls:2.05%
—
—
—
—
—
—
—
—
—
—
14
92
103
1078
15
24
102
1146
—
—
—
—
—
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
1.4e-01
1.9e+00
—
—
—
9.0e-01
3.3e-01
cases:10.26%
controls:9.06%
cases:15.38%
controls:2.56%
—
—
—
—
—
—
cases:6.54%
controls:2.77%
cases:12.05%
controls:8.94%
12
106
105
1064
18
30
99
1140
—
—
—
7
31
100
1088
10
79
73
805
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
3.6e-01
4.4e-01
1.9e+00
—
1.0e+00
4.1e-01
2.2e-01
cases:52.99%
controls:44.10%
cases:25.64%
controls:18.21%
cases:16.24%
controls:2.74%
—
—
cases:6.90%
controls:2.65%
cases:25.23%
controls:18.23%
cases:39.76%
controls:34.62%
62
516
55
654
30
213
87
957
19
32
98
1138
—
8
31
108
1137
27
204
80
915
33
306
50
578
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
3.6e-01
4.4e-01
1.9e+00
—
1.0e+00
4.1e-01
2.2e-01
cases:52.99%
controls:44.10%
cases:25.64%
controls:18.21%
cases:16.24%
controls:2.74%
—
—
cases:6.90%
controls:2.65%
cases:25.23%
controls:18.23%
cases:39.76%
controls:34.62%
62
516
55
654
30
213
87
957
19
32
98
1138
—
8
31
108
1137
27
204
80
915
33
306
50
578
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
8.1e-01
6.4e-01
1.6e+00
—
1.9e+00
9.2e-01
8.4e-01
cases:6.84%
controls:3.16%
cases:4.27%
controls:2.31%
cases:5.13%
controls:1.11%
—
—
cases:6.03%
controls:0.94%
cases:7.48%
controls:3.13%
cases:14.46%
controls:6.79%
8
37
109
1133
5
27
112
1143
6
13
111
1157
—
7
11
109
1157
8
35
99
1084
12
60
71
824
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
1.2e+00
1.9e+00
1.0e+50
—
—
—
1.2e+00
cases:8.55%
controls:2.74%
cases:5.98%
controls:0.94%
cases:6.84%
controls:0.00%
—
—
—
—
—
—
cases:13.25%
controls:4.19%
10
32
107
1138
7
11
110
1159
8
0
109
1170
—
—
—
11
37
72
847
pH of Specimen
17433-4 [3019225]
17433-4 [3019225]
2.3e-01
—
—
—
—
1.1e+00
1.9e+00
cases:4.27%
controls:3.42%
—
—
—
—
—
—
—
—
cases:4.67%
controls:1.61%
cases:20.48%
controls:3.73%
5
40
112
1130
—
—
—
—
5
18
102
1101
17
33
66
851
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
2.1e-01
3.5e-01
1.2e+00
1.0e+50
1.9e+00
3.3e-01
-3.3e-01
cases:16.24%
controls:13.59%
cases:16.24%
controls:12.05%
cases:9.40%
controls:3.08%
cases:5.13%
controls:0.00%
cases:12.07%
controls:2.05%
cases:14.95%
controls:11.26%
cases:25.30%
controls:32.01%
19
159
98
1011
19
141
98
1029
11
36
106
1134
6
0
111
1170
14
24
102
1144
16
126
91
993
21
283
62
601
Taking care of patient’s/customer’s hygiene
SPAT1137 [2001700238]
SPAT1137 [2001700238]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:1.47%
—
—
—
—
—
—
7
13
76
871
Body height measure
50373000 [4177340]
50373000 [4177340]
-6.9e-01
-3.5e-01
1.8e+00
—
—
1.0e+50
1.0e+50
cases:13.68%
controls:24.02%
cases:6.84%
controls:9.40%
cases:6.84%
controls:1.20%
—
—
—
—
cases:7.48%
controls:0.00%
cases:26.51%
controls:0.00%
16
281
101
889
8
110
109
1060
8
14
109
1156
—
—
8
0
99
1119
22
0
61
884
Body mass index
60621009 [4245997]
60621009 [4245997]
-7.6e-01
-3.4e-01
1.8e+00
—
—
1.0e+50
1.0e+50
cases:12.82%
controls:23.85%
cases:6.84%
controls:9.32%
cases:6.84%
controls:1.20%
—
—
—
—
cases:7.48%
controls:0.00%
cases:26.51%
controls:0.00%
15
279
102
891
8
109
109
1061
8
14
109
1156
—
—
8
0
99
1119
22
0
61
884
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
3.0e-01
1.2e-01
1.7e+00
—
1.8e+00
8.8e-01
-3.6e-02
cases:18.80%
controls:14.70%
cases:9.40%
controls:8.46%
cases:4.27%
controls:0.77%
—
—
cases:7.76%
controls:1.37%
cases:18.69%
controls:8.67%
cases:22.89%
controls:23.53%
22
172
95
998
11
99
106
1071
5
9
112
1161
—
9
16
107
1152
20
97
87
1022
19
208
64
676
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
5.9e-01
1.1e+00
1.7e+00
—
—
1.1e+00
1.8e+00
cases:5.98%
controls:3.42%
cases:6.84%
controls:2.48%
cases:4.27%
controls:0.77%
—
—
—
—
cases:5.61%
controls:1.88%
cases:26.51%
controls:5.66%
7
40
110
1130
8
29
109
1141
5
9
112
1161
—
—
6
21
101
1098
22
50
61
834
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
6.4e-01
4.4e-01
1.5e+00
—
1.8e+00
5.4e-01
2.2e-01
cases:16.24%
controls:9.32%
cases:9.40%
controls:6.24%
cases:7.69%
controls:1.88%
—
—
cases:8.62%
controls:1.54%
cases:10.28%
controls:6.26%
cases:15.66%
controls:13.01%
19
109
98
1061
11
73
106
1097
9
22
108
1148
—
10
18
106
1150
11
70
96
1049
13
115
70
769
Actinic keratosis
L57.0 [45591640]
L57.0 [45591640]
1.8e+00
1.7e+00
—
—
—
—
—
cases:7.69%
controls:1.37%
cases:4.27%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
9
16
108
1154
5
9
112
1161
—
—
—
—
—
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
94759-8 [586526]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:14.46%
controls:2.83%
—
—
—
—
—
—
12
25
71
859
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
SPAT1222 [2001700323]
—
1.5e+00
—
—
—
—
1.8e+00
—
—
cases:5.13%
controls:1.20%
—
—
—
—
—
—
—
—
cases:19.28%
controls:3.96%
—
6
14
111
1156
—
—
—
—
16
35
67
849
Gas panel - Capillary blood
24337-8 [3022313]
24337-8 [3022313]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:2.38%
—
—
—
—
—
—
10
21
73
863
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
72720-6 [43055554]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:2.71%
—
—
—
—
—
—
11
24
72
860
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
FM1EE [2001303307]
7.2e-01
1.7e+00
—
—
—
9.1e-01
6.9e-01
cases:12.82%
controls:6.67%
cases:10.26%
controls:2.05%
—
—
—
—
—
—
cases:5.61%
controls:2.32%
cases:14.46%
controls:7.81%
15
78
102
1092
12
24
105
1146
—
—
—
6
26
101
1093
12
69
71
815
Body CT examination
JN4AD [2001310897]
JN4AD [2001310897]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:1.92%
—
—
—
—
—
—
8
17
75
867
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
9.2e-01
1.7e+00
1.0e+50
1.0e+50
—
—
1.5e+00
cases:12.82%
controls:5.56%
cases:7.69%
controls:1.54%
cases:10.26%
controls:0.00%
cases:4.27%
controls:0.00%
—
—
—
—
cases:6.02%
controls:1.36%
15
65
102
1105
9
18
108
1152
12
0
105
1170
5
0
112
1170
—
—
5
12
78
872
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
SPAT1230 [2001700331]
1.0e+00
—
—
—
—
—
1.7e+00
cases:10.26%
controls:3.93%
—
—
—
—
—
—
—
—
—
—
cases:15.66%
controls:3.39%
12
46
105
1124
—
—
—
—
—
13
30
70
854
pH of Capillary blood
2745-8 [3009343]
2745-8 [3009343]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:2.83%
—
—
—
—
—
—
11
25
72
859
Other and unspecified abdominal pain
R10.4 [45568113]
R10.4 [45568113]
5.7e-01
1.1e+00
—
—
—
1.7e+00
3.3e-01
cases:9.40%
controls:5.56%
cases:5.13%
controls:1.79%
—
—
—
—
—
—
cases:7.48%
controls:1.52%
cases:8.43%
controls:6.22%
11
65
106
1105
6
21
111
1149
—
—
—
8
17
99
1102
7
55
76
829
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
9.3e-01
1.7e+00
—
—
—
1.3e+00
8.7e-01
cases:9.40%
controls:3.93%
cases:10.26%
controls:2.14%
—
—
—
—
—
—
cases:8.41%
controls:2.50%
cases:15.66%
controls:7.24%
11
46
106
1124
12
25
105
1145
—
—
—
9
28
98
1091
13
64
70
820
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
J44.8 [45586673]
—
1.3e+00
—
—
—
1.7e+00
1.6e+00
—
—
cases:4.27%
controls:1.20%
—
—
—
—
—
—
cases:5.61%
controls:1.07%
cases:12.05%
controls:2.60%
—
5
14
112
1156
—
—
—
6
12
101
1107
10
23
73
861
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
5.0e-01
6.5e-01
—
—
-1.0e+50
1.6e+00
9.6e-01
cases:8.55%
controls:5.38%
cases:5.13%
controls:2.74%
—
—
—
—
cases:0.00%
controls:0.86%
cases:11.21%
controls:2.41%
cases:12.05%
controls:4.98%
10
63
107
1107
6
32
111
1138
—
—
0
10
116
1158
12
27
95
1092
10
44
73
840
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
2020-6 [3023024]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:2.94%
—
—
—
—
—
—
11
26
72
858
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
5.9e-01
—
—
—
—
—
1.6e+00
cases:5.13%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:2.38%
6
34
111
1136
—
—
—
—
—
9
21
74
863
Creatine kinase.MB [Mass/volume] in Serum or Plasma
13969-1 [3005785]
13969-1 [3005785]
1.0e+00
—
—
—
—
—
1.6e+00
cases:5.98%
controls:2.22%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:2.38%
7
26
110
1144
—
—
—
—
—
9
21
74
863
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
5.9e-01
—
—
—
—
—
1.6e+00
cases:5.13%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:2.38%
6
34
111
1136
—
—
—
—
—
9
21
74
863
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
5.9e-01
—
—
—
—
—
1.6e+00
cases:5.13%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:2.38%
6
34
111
1136
—
—
—
—
—
9
21
74
863
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
5.9e-01
—
—
—
—
—
1.6e+00
cases:5.13%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:2.38%
6
34
111
1136
—
—
—
—
—
9
21
74
863
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
5.9e-01
—
—
—
—
—
1.6e+00
cases:5.13%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:2.38%
6
34
111
1136
—
—
—
—
—
9
21
74
863
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
5.9e-01
1.6e+00
—
—
—
4.8e-01
7.4e-01
cases:17.95%
controls:10.77%
cases:14.53%
controls:3.33%
—
—
—
—
—
—
cases:4.67%
controls:2.95%
cases:18.07%
controls:9.50%
21
126
96
1044
17
39
100
1131
—
—
—
5
33
102
1086
15
84
68
800
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
7.6e-01
—
—
—
—
—
1.6e+00
cases:7.69%
controls:3.76%
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:3.05%
9
44
108
1126
—
—
—
—
—
11
27
72
857
FEV1
20150-9 [3024653]
20150-9 [3024653]
7.6e-01
—
—
—
—
—
1.6e+00
cases:7.69%
controls:3.76%
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:3.05%
9
44
108
1126
—
—
—
—
—
11
27
72
857
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
7.6e-01
—
—
—
—
—
1.6e+00
cases:7.69%
controls:3.76%
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:3.05%
9
44
108
1126
—
—
—
—
—
11
27
72
857
Spinal stenosis
M48.0 [45557888]
M48.0 [45557888]
1.6e+00
1.5e+00
—
1.0e+50
—
1.3e+00
7.4e-01
cases:11.97%
controls:2.74%
cases:5.98%
controls:1.37%
—
—
cases:4.27%
controls:0.00%
—
—
cases:5.61%
controls:1.61%
cases:8.43%
controls:4.19%
14
32
103
1138
7
16
110
1154
—
5
0
112
1170
—
6
18
101
1101
7
37
76
847
Skin symptom/complaint other
S29 [2002000993]
S29 [2002000993]
1.6e+00
1.2e+00
—
—
—
—
1.1e+00
cases:15.38%
controls:3.68%
cases:4.27%
controls:1.37%
—
—
—
—
—
—
—
—
cases:13.25%
controls:4.98%
18
43
99
1127
5
16
112
1154
—
—
—
—
11
44
72
840
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
5.1e-01
1.5e+00
—
—
—
1.1e+00
8.4e-01
cases:5.98%
controls:3.68%
cases:8.55%
controls:1.97%
—
—
—
—
—
—
cases:6.54%
controls:2.32%
cases:18.07%
controls:8.71%
7
43
110
1127
10
23
107
1147
—
—
—
7
26
100
1093
15
77
68
807
Spinalanesthesia
WX320 [2001310799]
WX320 [2001310799]
8.4e-01
1.4e+00
—
—
—
1.2e+00
1.5e+00
cases:11.97%
controls:5.56%
cases:7.69%
controls:1.97%
—
—
—
—
—
—
cases:4.67%
controls:1.43%
cases:15.66%
controls:3.85%
14
65
103
1105
9
23
108
1147
—
—
—
5
16
102
1103
13
34
70
850
Functional capacity evaluation
443351003 [40481051]
443351003 [40481051]
3.7e-01
—
—
—
—
—
1.5e+00
cases:4.27%
controls:2.99%
—
—
—
—
—
—
—
—
—
—
cases:15.66%
controls:3.85%
5
35
112
1135
—
—
—
—
—
13
34
70
850
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
6.4e-01
1.5e+00
—
—
-1.0e+50
1.2e+00
8.1e-01
cases:5.98%
controls:3.25%
cases:7.69%
controls:1.79%
—
—
—
—
cases:0.00%
controls:0.60%
cases:6.54%
controls:2.14%
cases:16.87%
controls:8.26%
7
38
110
1132
9
21
108
1149
—
—
0
7
116
1161
7
24
100
1095
14
73
69
811
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
1.5e+00
1.7e+00
—
—
—
1.5e+00
4.7e-01
cases:7.69%
controls:1.79%
cases:5.13%
controls:0.94%
—
—
—
—
—
—
cases:5.61%
controls:1.25%
cases:8.43%
controls:5.43%
9
21
108
1149
6
11
111
1159
—
—
—
6
14
101
1105
7
48
76
836
Pure hypercholesterolaemia
E78.01 [2000501514]
E78.01 [2000501514]
6.4e-01
1.5e+00
—
—
—
3.6e-01
6.9e-01
cases:11.97%
controls:6.67%
cases:11.11%
controls:2.74%
—
—
—
—
—
—
cases:4.67%
controls:3.31%
cases:16.87%
controls:9.28%
14
78
103
1092
13
32
104
1138
—
—
—
5
37
102
1082
14
82
69
802
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
70200-1 [42868674]
6.8e-01
9.2e-01
—
—
—
2.6e-01
1.5e+00
cases:11.11%
controls:5.98%
cases:10.26%
controls:4.36%
—
—
—
—
—
—
cases:5.61%
controls:4.38%
cases:25.30%
controls:7.13%
13
70
104
1100
12
51
105
1119
—
—
—
6
49
101
1070
21
63
62
821
oxycodone and naloxone; oral
N02AA55 [21604265]
N02AA55 [21604265]
1.5e+00
—
—
—
1.0e+50
1.2e+00
1.0e+00
cases:9.40%
controls:2.31%
—
—
—
—
—
—
cases:4.31%
controls:0.00%
cases:4.67%
controls:1.43%
cases:15.66%
controls:6.22%
11
27
106
1143
—
—
—
5
0
111
1168
5
16
102
1103
13
55
70
829
apixaban; oral
B01AF02 [43534762]
B01AF02 [43534762]
—
8.7e-01
1.7e+00
—
—
1.5e+00
6.5e-01
—
—
cases:5.13%
controls:2.22%
cases:5.98%
controls:1.20%
—
—
—
—
cases:12.15%
controls:3.13%
cases:13.25%
controls:7.35%
—
6
26
111
1144
7
14
110
1156
—
—
13
35
94
1084
11
65
72
819
Recording of ECG
SPAT1097 [2001700198]
SPAT1097 [2001700198]
1.5e+00
1.4e+00
—
—
—
—
1.6e+00
cases:11.97%
controls:3.08%
cases:5.98%
controls:1.54%
—
—
—
—
—
—
—
—
cases:9.64%
controls:2.15%
14
36
103
1134
7
18
110
1152
—
—
—
—
8
19
75
865
Weakness/tiredness general
A04 [2002000145]
A04 [2002000145]
9.5e-01
-1.0e+50
—
—
—
—
1.4e+00
cases:5.98%
controls:2.39%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
cases:15.66%
controls:4.19%
7
28
110
1142
0
11
117
1159
—
—
—
—
13
37
70
847
More than three and less than five hours
ZXE20 [2001311408]
ZXE20 [2001311408]
1.4e+00
—
—
—
—
—
—
cases:10.26%
controls:2.65%
—
—
—
—
—
—
—
—
—
—
—
—
12
31
105
1139
—
—
—
—
—
—
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
8.1e-01
1.3e+00
—
—
—
1.2e+00
1.4e+00
cases:6.84%
controls:3.16%
cases:8.55%
controls:2.56%
—
—
—
—
—
—
cases:5.61%
controls:1.70%
cases:16.87%
controls:4.64%
8
37
109
1133
10
30
107
1140
—
—
—
6
19
101
1100
14
41
69
843
Abdominal CT examination
JN3AD [2001305554]
JN3AD [2001305554]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:14.46%
controls:3.96%
—
—
—
—
—
—
12
35
71
849
Erysipelas
A46 [45561706]
A46 [45561706]
7.8e-01
1.5e+00
—
—
—
—
1.4e+00
cases:5.98%
controls:2.82%
cases:4.27%
controls:1.03%
—
—
—
—
—
—
—
—
cases:14.46%
controls:3.96%
7
33
110
1137
5
12
112
1158
—
—
—
—
12
35
71
849
Psychiatry
26 [38004469]
26 [38004469]
3.0e-01
5.1e-01
—
—
—
7.3e-01
1.4e+00
cases:7.69%
controls:5.81%
cases:5.98%
controls:3.68%
—
—
—
—
—
—
cases:5.61%
controls:2.77%
cases:14.46%
controls:4.07%
9
68
108
1102
7
43
110
1127
—
—
—
6
31
101
1088
12
36
71
848
mirtazapine; oral
N06AX11 [21604740]
N06AX11 [21604740]
7.1e-01
5.3e-01
—
—
1.4e+00
1.4e+00
8.2e-01
cases:16.24%
controls:8.72%
cases:8.55%
controls:5.21%
—
—
—
—
cases:5.17%
controls:1.37%
cases:16.82%
controls:4.92%
cases:21.69%
controls:10.86%
19
102
98
1068
10
61
107
1109
—
—
6
16
110
1152
18
55
89
1064
18
96
65
788
Gastroenterology
10 [38004455]
10 [38004455]
4.8e-01
1.0e+00
—
—
—
1.3e+00
7.5e-01
cases:12.82%
controls:8.38%
cases:10.26%
controls:4.02%
—
—
—
—
—
—
cases:12.15%
controls:3.49%
cases:15.66%
controls:8.03%
15
98
102
1072
12
47
105
1123
—
—
—
13
39
94
1080
13
71
70
813
Fever
A03 [2002000144]
A03 [2002000144]
1.3e+00
—
—
—
—
—
8.7e-01
cases:9.40%
controls:2.65%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.60%
11
31
106
1139
—
—
—
—
—
5
23
78
861
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
1.3e+00
1.1e+00
—
—
—
9.8e-01
1.0e+00
cases:13.68%
controls:4.19%
cases:6.84%
controls:2.39%
—
—
—
—
—
—
cases:7.48%
controls:2.95%
cases:18.07%
controls:7.35%
16
49
101
1121
8
28
109
1142
—
—
—
8
33
99
1086
15
65
68
819
Pneumonia, unspecified
J18.9 [45601123]
J18.9 [45601123]
7.4e-01
1.1e+00
—
—
—
—
1.2e+00
cases:8.55%
controls:4.27%
cases:5.13%
controls:1.79%
—
—
—
—
—
—
—
—
cases:18.07%
controls:6.22%
10
50
107
1120
6
21
111
1149
—
—
—
—
15
55
68
829
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
1.2e+00
1.4e+00
—
—
—
1.0e+00
1.2e+00
cases:8.55%
controls:2.65%
cases:5.98%
controls:1.54%
—
—
—
—
—
—
cases:5.61%
controls:2.06%
cases:19.28%
controls:7.01%
10
31
107
1139
7
18
110
1152
—
—
—
6
23
101
1096
16
62
67
822
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
1.1e+00
5.8e-01
—
—
—
4.2e-01
3.7e-01
cases:19.66%
controls:7.35%
cases:7.69%
controls:4.44%
—
—
—
—
—
—
cases:5.61%
controls:3.75%
cases:14.46%
controls:10.41%
23
86
94
1084
9
52
108
1118
—
—
—
6
42
101
1077
12
92
71
792
Shoulder symptom/complaint
L08 [2002000632]
L08 [2002000632]
1.1e+00
—
—
—
—
—
7.4e-01
cases:13.68%
controls:5.04%
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:6.11%
16
59
101
1111
—
—
—
—
—
10
54
73
830
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
8.9e-01
8.0e-01
—
—
—
1.1e+00
5.0e-01
cases:15.38%
controls:6.92%
cases:8.55%
controls:4.02%
—
—
—
—
—
—
cases:14.02%
controls:5.18%
cases:22.89%
controls:15.27%
18
81
99
1089
10
47
107
1123
—
—
—
15
58
92
1061
19
135
64
749
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
1.1e+00
—
—
—
—
—
1.2e+00
cases:11.97%
controls:4.36%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:3.51%
14
51
103
1119
—
—
—
—
—
9
31
74
853
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
1.1e+00
1.7e+00
1.0e+50
—
—
—
—
cases:12.82%
controls:4.79%
cases:5.98%
controls:1.11%
cases:5.13%
controls:0.00%
—
—
—
—
—
—
—
—
15
56
102
1114
7
13
110
1157
6
0
111
1170
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
9.5e-02
7.2e-01
—
—
1.8e+00
3.9e-01
1.1e+00
cases:15.38%
controls:14.19%
cases:12.82%
controls:6.67%
—
—
—
—
cases:4.31%
controls:0.77%
cases:11.21%
controls:7.86%
cases:46.99%
controls:23.64%
18
166
99
1004
15
78
102
1092
—
—
5
9
111
1159
12
88
95
1031
39
209
44
675
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
48065-7 [3051714]
6.6e-01
—
—
—
—
7.2e-01
1.0e+00
cases:11.97%
controls:6.58%
—
—
—
—
—
—
—
—
cases:4.67%
controls:2.32%
cases:24.10%
controls:10.18%
14
77
103
1093
—
—
—
—
5
26
102
1093
20
90
63
794
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
2.3e-01
1.4e+00
—
—
—
1.1e+00
1.0e+00
cases:4.27%
controls:3.42%
cases:7.69%
controls:2.05%
—
—
—
—
—
—
cases:6.54%
controls:2.23%
cases:20.48%
controls:8.60%
5
40
112
1130
9
24
108
1146
—
—
—
7
25
100
1094
17
76
66
808
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
SPAT1256 [2001700357]
6.0e-01
5.3e-01
—
—
—
6.7e-01
9.9e-01
cases:24.79%
controls:15.30%
cases:11.11%
controls:6.84%
—
—
—
—
—
—
cases:14.02%
controls:7.69%
cases:32.53%
controls:15.16%
29
179
88
991
13
80
104
1090
—
—
—
15
86
92
1033
27
134
56
750
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5794-3 [3011397]
9.8e-01
4.4e-01
—
—
—
7.3e-01
5.4e-02
cases:15.38%
controls:6.41%
cases:6.84%
controls:4.53%
—
—
—
—
—
—
cases:11.21%
controls:5.72%
cases:14.46%
controls:13.80%
18
75
99
1095
8
53
109
1117
—
—
—
12
64
95
1055
12
122
71
762
amoxicillin; oral, parenteral
J01CA04 [21602823]
J01CA04 [21602823]
2.2e-01
9.6e-01
—
—
—
8.1e-01
3.6e-01
cases:28.21%
controls:24.02%
cases:15.38%
controls:6.50%
—
—
—
—
—
—
cases:13.08%
controls:6.26%
cases:28.92%
controls:22.06%
33
281
84
889
18
76
99
1094
—
—
—
14
70
93
1049
24
195
59
689
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
14685-2 [3009035]
9.2e-01
5.1e-01
-1.0e+50
—
—
1.1e+00
5.4e-01
cases:17.95%
controls:8.03%
cases:5.98%
controls:3.68%
cases:0.00%
controls:0.60%
—
—
—
—
cases:8.41%
controls:3.04%
cases:15.66%
controls:9.73%
21
94
96
1076
7
43
110
1127
0
7
117
1163
—
—
9
34
98
1085
13
86
70
798
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
5.1e-01
4.5e-01
1.4e+00
—
1.5e+00
8.8e-01
1.5e-01
cases:25.64%
controls:17.18%
cases:15.38%
controls:10.43%
cases:5.13%
controls:1.37%
—
—
cases:7.76%
controls:1.88%
cases:24.30%
controls:11.80%
cases:34.94%
controls:31.67%
30
201
87
969
18
122
99
1048
6
16
111
1154
—
9
22
107
1146
26
132
81
987
29
280
54
604
bisoprolol; oral
C07AB07 [21601689]
C07AB07 [21601689]
5.3e-01
6.6e-01
-3.8e-01
—
3.9e-01
6.0e-01
8.7e-01
cases:30.77%
controls:20.68%
cases:29.06%
controls:17.52%
cases:4.27%
controls:6.15%
—
—
cases:7.76%
controls:5.39%
cases:28.04%
controls:17.61%
cases:43.37%
controls:24.21%
36
242
81
928
34
205
83
965
5
72
112
1098
—
9
63
107
1105
30
197
77
922
36
214
47
670
Telehealth
OMOP5556618 [722455]
OMOP5556618 [722455]
2.3e-01
8.2e-01
1.2e+00
—
1.0e+00
4.6e-01
3.2e-01
cases:49.57%
controls:43.85%
cases:28.21%
controls:14.70%
cases:6.84%
controls:2.14%
—
—
cases:6.03%
controls:2.23%
cases:21.50%
controls:14.75%
cases:27.71%
controls:21.83%
58
513
59
657
33
172
84
998
8
25
109
1145
—
7
26
109
1142
23
165
84
954
23
193
60
691
Pelvic artery PTA with stent
PD3YT [2001309241]
PD3YT [2001309241]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
117
1165
—
—
—
—
—
—
spironolactone; oral
C03DA01 [21601534]
C03DA01 [21601534]
—
1.0e+00
—
—
—
1.0e+00
9.3e-01
—
—
cases:5.13%
controls:1.88%
—
—
—
—
—
—
cases:4.67%
controls:1.70%
cases:8.43%
controls:3.51%
—
6
22
111
1148
—
—
—
5
19
102
1100
7
31
76
853
azithromycin; oral, parenteral
J01FA10 [21602978]
J01FA10 [21602978]
4.1e-02
—
—
—
—
-1.0e+50
—
cases:6.84%
controls:6.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.43%
—
—
8
77
109
1093
—
—
—
—
0
16
107
1103
—
aciclovir; oral, parenteral
J05AB01 [21603131]
J05AB01 [21603131]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
—
0
13
117
1157
—
—
—
—
—
oxcarbazepine; oral
N03AF02 [21604418]
N03AF02 [21604418]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
cases:0.00%
controls:0.79%
—
—
—
—
—
0
7
107
1112
0
7
83
877
betamethasone
S03BA03 [21605203]
S03BA03 [21605203]
3.1e-01
—
—
—
—
—
8.3e-01
cases:4.27%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.71%
5
37
112
1133
—
—
—
—
—
5
24
78
860
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
32294-1 [3020682]
3.3e-01
9.4e-02
—
—
—
1.3e-01
3.5e-01
cases:15.38%
controls:11.54%
cases:9.40%
controls:8.63%
—
—
—
—
—
—
cases:12.15%
controls:10.81%
cases:31.33%
controls:24.32%
18
135
99
1035
11
101
106
1069
—
—
—
13
121
94
998
26
215
57
669
Epidermal cyst
L72.0 [45591644]
L72.0 [45591644]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
879
Intraoral radiographic dental examination
EB1AA [2001301903]
EB1AA [2001301903]
2.6e-01
6.7e-01
—
—
-1.0e+50
-3.1e-01
1.3e-01
cases:27.35%
controls:22.56%
cases:12.82%
controls:7.01%
—
—
—
—
cases:0.00%
controls:0.86%
cases:4.67%
controls:6.26%
cases:20.48%
controls:18.44%
32
264
85
906
15
82
102
1088
—
—
0
10
116
1158
5
70
102
1049
17
163
66
721
Pain in thoracic spine
M54.6 [45606247]
M54.6 [45606247]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
0
5
107
1114
—
Screening procedure
SPAT1324 [2001700425]
SPAT1324 [2001700425]
0.0e+00
-1.0e+50
—
—
—
—
—
cases:5.98%
controls:5.98%
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
7
70
110
1100
0
13
117
1157
—
—
—
—
—
telithromycin; oral
J01FA15 [21602983]
J01FA15 [21602983]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
117
1162
—
—
—
—
—
—
Sleep disturbance
P06 [2002000803]
P06 [2002000803]
1.5e+00
—
—
—
—
—
—
cases:6.84%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
8
18
109
1152
—
—
—
—
—
—
triamcinolone and antiseptics
D07BB03 [21602150]
D07BB03 [21602150]
8.3e-01
—
—
—
—
—
—
cases:5.13%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
—
—
6
27
111
1143
—
—
—
—
—
—
Change in the oral mucosa UNS
K13.79 [2000502894]
K13.79 [2000502894]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
6
83
878
CT of neck arteries
PA6AD [2001308692]
PA6AD [2001308692]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
879
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
4.9e-01
1.1e+00
-1.0e+50
—
-1.0e+50
9.5e-01
1.0e+00
cases:5.98%
controls:3.76%
cases:6.84%
controls:2.48%
cases:0.00%
controls:0.43%
—
—
cases:0.00%
controls:0.68%
cases:5.61%
controls:2.23%
cases:13.25%
controls:5.20%
7
44
110
1126
8
29
109
1141
0
5
117
1165
—
0
8
116
1160
6
25
101
1094
11
46
72
838
Administration of medicine
SPAT1254 [2001700355]
SPAT1254 [2001700355]
5.3e-01
1.4e+00
—
-1.0e+50
—
—
8.3e-01
cases:5.13%
controls:3.08%
cases:5.13%
controls:1.37%
—
—
cases:0.00%
controls:0.43%
—
—
—
—
cases:7.23%
controls:3.28%
6
36
111
1134
6
16
111
1154
—
0
5
117
1165
—
—
6
29
77
855
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
2.7e-01
1.0e-01
1.9e+00
—
—
4.6e-01
4.7e-01
cases:17.95%
controls:14.36%
cases:9.40%
controls:8.55%
cases:4.27%
controls:0.68%
—
—
—
—
cases:13.08%
controls:8.67%
cases:37.35%
controls:27.15%
21
168
96
1002
11
100
106
1070
5
8
112
1162
—
—
14
97
93
1022
31
240
52
644
timolol, combinations
S01ED51 [21603705]
S01ED51 [21603705]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
7
117
1163
—
—
—
—
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
2885-2 [3020630]
8.3e-01
1.2e+00
—
—
—
—
7.0e-01
cases:5.13%
controls:2.31%
cases:4.27%
controls:1.28%
—
—
—
—
—
—
—
—
cases:7.23%
controls:3.73%
6
27
111
1143
5
15
112
1155
—
—
—
—
6
33
77
851
Left side
ZXA05 [2001311347]
ZXA05 [2001311347]
9.1e-01
—
—
—
—
—
—
cases:11.11%
controls:4.79%
—
—
—
—
—
—
—
—
—
—
—
—
13
56
104
1114
—
—
—
—
—
—
Achilles tendinitis
M76.6 [45596682]
M76.6 [45596682]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
10
117
1160
—
—
—
—
—
0
6
83
878
dexrabeprazole
A02BC07 [45893509]
A02BC07 [45893509]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.88%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.38%
0
22
117
1148
—
—
—
—
—
0
21
83
863
pH of Urine by Test strip
5803-2 [3022621]
5803-2 [3022621]
6.4e-01
—
—
—
—
—
—
cases:4.27%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
—
—
5
27
112
1143
—
—
—
—
—
—
Teeth/gum symptom/complaint
D19 [2002000318]
D19 [2002000318]
-4.7e-02
—
—
—
-1.0e+50
—
2.6e-01
cases:7.69%
controls:8.03%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
cases:10.84%
controls:8.60%
9
94
108
1076
—
—
—
0
6
116
1162
—
9
76
74
808
Benign neoplasm: Sigmoid colon
D12.5 [45552326]
D12.5 [45552326]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
117
1163
—
—
—
—
—
—
Contusion of shoulder and upper arm
S40.0 [45563774]
S40.0 [45563774]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
9
83
875
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
117
1160
—
—
—
—
—
—
Clinical photography of mouth and teeth
SBB00 [2001310298]
SBB00 [2001310298]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
6
117
1164
—
—
—
—
—
0
5
83
879
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
14771-0 [3018251]
2.2e-01
4.4e-01
5.9e-01
—
1.2e+00
3.1e-01
2.8e-01
cases:54.70%
controls:49.32%
cases:41.88%
controls:31.79%
cases:5.98%
controls:3.42%
—
—
cases:10.34%
controls:3.51%
cases:41.12%
controls:33.87%
cases:75.90%
controls:70.36%
64
577
53
593
49
372
68
798
7
40
110
1130
—
12
41
104
1127
44
379
63
740
63
622
20
262
verapamil; oral, parenteral
C08DA01 [21601767]
C08DA01 [21601767]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
117
1164
—
—
—
—
—
—
Varicose veins of lower extremities without ulcer or inflammation
I83.9 [45552859]
I83.9 [45552859]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
117
1158
—
—
—
—
—
—
lovastatin; oral
C10AA02 [21601857]
C10AA02 [21601857]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
117
1163
—
—
—
—
—
—
Fractional oxyhemoglobin in Capillary blood
2715-1 [3022806]
2715-1 [3022806]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
879
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
D01AC20 [21601936]
6.1e-01
—
—
—
—
—
3.0e-01
cases:6.84%
controls:3.85%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:4.52%
8
45
109
1125
—
—
—
—
—
5
40
78
844
Gout
M10 [45533711]
M10 [45533711]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
0
15
117
1155
—
—
—
—
0
6
107
1113
—
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
4.3e-01
—
—
—
—
—
7.9e-01
cases:7.69%
controls:5.13%
—
—
—
—
—
—
—
—
—
—
cases:15.66%
controls:7.81%
9
60
108
1110
—
—
—
—
—
13
69
70
815
Contusion of eyelid and periocular area
S00.1 [45553759]
S00.1 [45553759]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
5
117
1165
—
—
—
—
—
0
5
83
879
Telephone prescription or other care instructions
WZB00 [2001310884]
WZB00 [2001310884]
-3.7e-01
—
—
—
—
—
5.8e-01
cases:5.98%
controls:8.46%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:4.19%
7
99
110
1071
—
—
—
—
—
6
37
77
847
Knee X-ray examination without contrast
NG1AA [2001308049]
NG1AA [2001308049]
1.3e+00
1.5e+00
—
—
—
—
9.7e-01
cases:8.55%
controls:2.56%
cases:5.13%
controls:1.20%
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.38%
10
30
107
1140
6
14
111
1156
—
—
—
—
5
21
78
863
Preretinal fibrosis of the macula
H35.38 [2000502318]
H35.38 [2000502318]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
879
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
95941-1 [36031861]
—
—
—
—
—
—
9.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:3.05%
—
—
—
—
—
—
6
27
77
857
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
—
2.0e+00
—
—
—
—
8.3e-01
—
—
cases:4.27%
controls:0.60%
—
—
—
—
—
—
—
—
cases:8.43%
controls:3.85%
—
5
7
112
1163
—
—
—
—
7
34
76
850
valsartan, amlodipine and hydrochlorothiazide
C09DX01 [21601846]
C09DX01 [21601846]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
0
6
117
1164
0
7
117
1163
—
—
—
0
7
107
1112
—
Medication, disinfection of root canals
SGC00 [2001310392]
SGC00 [2001310392]
9.9e-01
—
—
—
—
-1.0e+50
—
cases:5.13%
controls:1.97%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
6
23
111
1147
—
—
—
—
0
7
107
1112
—
flucloxacillin; oral, parenteral
J01CF05 [21602857]
J01CF05 [21602857]
1.5e+00
—
—
—
1.0e+50
—
1.0e+00
cases:4.27%
controls:1.03%
—
—
—
—
—
—
cases:5.17%
controls:0.00%
—
—
cases:6.02%
controls:2.26%
5
12
112
1158
—
—
—
6
0
110
1168
—
5
20
78
864
pseudoephedrine, combinations; oral
R01BA52 [21603213]
R01BA52 [21603213]
1.6e-02
—
—
—
-1.0e+50
—
1.2e-01
cases:11.97%
controls:11.79%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
cases:10.84%
controls:9.73%
14
138
103
1032
—
—
—
0
7
116
1161
—
9
86
74
798
Caries limited to enamel
K02.0 [45576967]
K02.0 [45576967]
5.0e-01
—
—
—
—
-1.0e+50
1.8e-01
cases:5.13%
controls:3.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.52%
cases:6.02%
controls:5.09%
6
37
111
1133
—
—
—
—
0
17
107
1102
5
45
78
839
clopidogrel; oral
B01AC04 [21600989]
B01AC04 [21600989]
7.6e-01
7.5e-01
-1.0e+50
—
-1.0e+50
—
6.6e-01
cases:8.55%
controls:4.19%
cases:5.13%
controls:2.48%
cases:0.00%
controls:0.60%
—
—
cases:0.00%
controls:0.94%
—
—
cases:9.64%
controls:5.20%
10
49
107
1121
6
29
111
1141
0
7
117
1163
—
0
11
116
1157
—
8
46
75
838
chloramphenicol
S01AA01 [21603554]
S01AA01 [21603554]
8.2e-02
3.5e-01
—
—
—
6.6e-01
1.1e-01
cases:13.68%
controls:12.74%
cases:5.98%
controls:4.27%
—
—
—
—
—
—
cases:7.48%
controls:4.02%
cases:16.87%
controls:15.38%
16
149
101
1021
7
50
110
1120
—
—
—
8
45
99
1074
14
136
69
748
s-atenolol; oral
C07AB11 [21601693]
C07AB11 [21601693]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
0
10
117
1160
—
—
—
—
—
Diabetes, insulin-treated
103 [2001600103]
103 [2001600103]
2.3e-01
—
—
—
—
—
—
cases:4.27%
controls:3.42%
—
—
—
—
—
—
—
—
—
—
—
—
5
40
112
1130
—
—
—
—
—
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
103
516
9.32
18.53
4.7
2.7
—
—
estimate
—
0
0
66
260
4.53
14.89
4.0
2.2
—
—
—
0
0
40
131
4.12
11.11
8.8
8.1
1.32
1.23
mmol/l
0.04
33
110
21
25
9.98
10.61
3.3
1.6
—
—
—
0
0
38
144
3.43
8.26
6.2
6.5
1.06
1.03
mmol/l
0.21
38
136
37
145
3.27
7.55
9.4
7.8
105.05
103.90
mmol/l
0.81
37
145
72
415
2.91
7.28
6.6
4.2
50.80
42.10
ng/l
0.23
65
308
25
78
3.80
7.20
2.0
1.4
—
—
—
0
0
90
605
3.11
6.52
15.5
10.9
4.23
4.28
e9/l
0.08
85
526
42
191
2.87
6.51
2.9
1.9
—
—
—
0
0
62
346
2.68
6.44
6.1
3.5
1478.72
1311.62
ng/l
0.15
52
290
20
58
3.95
6.34
4.8
2.5
2.45
1.60
mmol/l
0.47
15
46
45
218
2.73
6.13
2.6
1.8
1.03
1.40
mg/l
0.47
36
180
78
502
2.66
5.86
10.2
6.4
1.19
1.21
mmol/l
1.63
73
461
16
36
4.98
5.30
1.8
1.6
—
—
—
0
0
17
51
3.73
5.11
2.7
1.3
—
—
—
0
0
16
38
4.71
5.06
2.1
1.7
—
—
—
0
0
24
98
2.82
4.40
4.9
4.5
2.73
2.12
mmol/l
0.22
19
81
37
189
2.40
4.32
4.0
3.2
0.81
0.81
mmol/l
0.05
37
178
14
37
4.15
4.06
4.7
2.9
52.59
207.97
mg/l
0.46
14
31
14
37
4.15
4.06
4.7
2.9
37.02
30.93
mg/l
0.37
14
31
15
49
3.36
3.97
3.2
2.8
—
—
—
0
0
84
616
2.29
3.96
3.2
3.2
—
—
—
0
0
17
61
3.09
3.88
2.7
1.5
—
—
—
0
0
94
728
2.48
3.82
6.0
3.3
60.93
49.77
u/l
0.78
89
691
39
216
2.21
3.71
5.1
3.7
42.90
299.80
ng/l
1.24
29
173
67
459
2.08
3.64
2.7
2.1
99.99
93.48
pmol/l
0.51
41
228
29
145
2.33
3.49
3.0
1.8
—
—
—
0
0
28
138
2.35
3.48
4.8
4.7
35.35
32.02
%
0.64
20
82
9
18
5.32
3.44
1.1
1.4
—
—
—
0
0
9
18
5.32
3.44
1.1
1.4
—
—
—
0
0
69
485
2.03
3.42
4.0
3.1
142.75
122.09
ug/l
0.36
64
461
7
10
7.36
3.41
1.0
1.3
—
—
—
0
0
25
123
2.31
3.10
2.2
3.4
9.82
9.57
umol/l
0.02
20
111
11
32
3.68
2.99
1.5
1.2
—
—
—
0
0
10
27
3.95
2.96
1.1
2.2
—
—
—
0
0
10
27
3.95
2.96
2.0
1.2
—
—
—
0
0
64
454
1.90
2.93
3.2
2.7
74.22
75.99
nmol/l
0.22
59
406
5
6
8.63
2.77
3.6
3.0
—
—
—
0
0
11
36
3.26
2.65
1.2
1.6
—
—
—
0
0
11
38
3.09
2.49
1.2
1.6
—
—
—
0
0
26
142
2.07
2.49
3.2
1.9
—
—
—
0
0
22
114
2.15
2.40
7.9
7.5
—
—
—
0
0
5
8
6.47
2.39
1.2
2.0
—
—
—
0
0
5
8
6.47
2.39
1.2
2.0
—
—
—
0
0
5
8
6.47
2.39
1.2
2.0
—
—
—
0
0
108
964
2.56
2.38
6.0
5.2
1.89
1.94
mu/l
0.13
101
886
16
74
2.35
2.27
3.4
2.7
230.87
204.84
ng/l
0.12
16
68
73
567
1.76
2.26
6.6
3.9
0.00
0.00
estimate
-0.00
11
120
37
236
1.83
2.25
7.6
4.3
1.02
1.02
kg/l
0.88
30
154
5
10
5.17
2.09
1.6
2.6
—
—
—
0
0
71
560
1.68
1.97
6.6
3.9
0.00
0.00
estimate
—
9
120
5
11
4.69
1.96
1.4
1.9
—
—
—
0
0
29
180
1.81
1.90
4.7
2.9
1.46
0.92
e6/l
0.64
17
101
8
28
2.99
1.90
1.3
1.3
—
—
—
0
0
72
574
1.66
1.88
6.5
3.9
0.30
0.00
estimate
—
10
111
110
1006
2.56
1.84
6.5
5.1
6.07
5.96
mmol/l
0.37
103
926
5
12
4.30
1.84
1.4
1.8
—
—
—
0
0
108
984
2.27
1.82
8.2
6.5
40.89
39.67
mmol/mol
0.51
102
923
12
54
2.36
1.81
3.6
2.6
0.66
0.61
%
0.14
12
54
9
36
2.62
1.78
1.1
1.6
—
—
—
0
0
107
963
2.30
1.77
5.0
4.4
1.32
1.31
mmol/l
0.08
100
877
8
30
2.79
1.76
2.9
2.3
4.74
3.62
g/l
—
8
30
8
30
2.79
1.76
1.1
1.7
—
—
—
0
0
5
13
3.97
1.73
1.8
4.9
607.80
988.77
mg
—
5
13
12
56
2.27
1.67
3.3
2.6
1.56
1.06
%
0.76
12
56
50
372
1.60
1.67
4.2
4.0
21.39
10.33
mg/mmol
0.44
35
235
5
14
3.68
1.63
1.0
1.1
125.60
105.07
%
—
5
14
7
26
2.80
1.61
1.1
1.6
—
—
—
0
0
26
165
1.74
1.58
5.8
3.0
4.69
2.33
e6/l
0.28
14
87
110
1019
2.33
1.57
5.8
5.3
4.45
4.60
mmol/l
0.75
104
946
5
15
3.43
1.54
1.4
1.1
—
—
—
0
0
7
28
2.59
1.47
1.3
1.3
—
—
—
0
0
6
23
2.69
1.38
1.2
1.2
—
—
—
0
0
109
1014
2.10
1.37
5.9
5.2
1.44
1.45
mmol/l
0.11
102
931
5
17
3.02
1.37
1.6
1.9
—
—
—
0
0
13
70
1.96
1.30
12.2
8.6
24.31
25.16
mmol/l
0.50
13
70
107
989
1.96
1.21
35.2
16.2
76.96
80.12
ml/min/173m2
0.73
98
932
7
30
2.42
1.14
1.0
1.6
—
—
—
0
0
7
31
2.34
1.12
1.1
1.4
—
—
—
0
0
5
21
2.44
1.10
1.0
1.2
—
—
—
0
0
5
21
2.44
1.10
1.2
1.6
—
—
—
0
0
35
263
1.47
1.05
1.3
1.3
2.56
0.81
u/ml
—
8
74
7
35
2.06
1.02
2.7
1.7
87.29
92.94
%
—
7
35
27
195
1.50
0.98
1.3
1.3
143.00
28.86
iu/ml
—
6
64
7
37
1.95
0.96
1.4
1.2
0.00
0.00
g/l
—
7
37
6
27
2.29
0.95
3.7
2.2
238.83
193.78
%
—
6
27
110
1040
1.96
0.94
6.1
5.9
2.56
2.68
mmol/l
0.61
103
960
6
31
1.98
0.85
1.2
1.2
—
—
—
0
0
17
114
1.57
0.85
4.7
3.4
—
—
—
0
0
24
177
1.45
0.79
1.3
1.4
45.71
10.24
u/ml
0.81
13
66
5
23
2.22
0.77
2.6
1.2
—
—
—
0
0
50
425
1.31
0.69
6.7
3.9
0.00
0.00
estimate
—
6
105
38
311
1.33
0.68
5.1
3.1
0.27
0.38
e6/l
0.41
32
228
11
71
1.61
0.64
1.6
2.6
78.00
59.88
ml/min/173m2
—
5
32
36
299
1.29
0.58
4.6
4.8
21.20
21.74
%
0.05
12
147
38
318
1.29
0.58
5.6
4.0
0.00
0.00
estimate
—
10
117
5
32
1.59
0.43
1.0
1.3
0.24
0.24
g/l
—
5
32
5
32
1.59
0.43
1.0
1.3
1.34
1.15
g/l
—
5
32
5
32
1.59
0.43
1.4
1.7
—
—
—
0
0
0
17
0.00
0.41
0.0
1.5
—
1.25
—
0
11
0
17
0.00
0.41
0.0
1.5
—
1.07
—
0
11
0
17
0.00
0.41
0.0
1.5
—
1.23
—
0
11
90
854
1.23
0.38
55.6
21.8
331.42
332.19
g/l
0.32
90
854
6
43
1.42
0.35
1.8
2.1
—
—
—
0
0
7
54
1.31
0.31
1.1
1.3
—
—
—
0
0
20
168
1.23
0.29
1.6
1.4
—
—
—
0
0
11
85
1.32
0.29
1.3
1.8
—
—
—
0
0
19
223
0.82
0.27
2.5
3.2
0.59
0.79
ug/l
1.36
14
140
45
488
0.87
0.25
2.0
2.0
1.38
1.38
mmol/l
0.02
40
407
0
10
0.00
0.21
0.0
1.1
—
165.59
—
0
10
0
10
0.00
0.21
0.0
4.4
—
83.30
—
0
10
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
35
319
1.14
0.21
6.1
3.4
0.00
0.00
estimate
—
5
98
11
94
1.19
0.13
1.4
1.9
—
—
—
0
0
15
140
1.08
0.04
1.2
1.4
—
—
—
0
0
10
93
1.08
0.02
1.4
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
9.57
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
8.27
—
0
6
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
8
85
0.94
-0.00
3.4
4.1
1.24
1.22
mmol/l
—
8
73
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: VWXY20_STERI_VAROT_PETTA_KIRURGISEN_TAI_MUUN_LAAKETIETEELLISEN_HOIDON_AIKANA – Failure of sterile precautions during surgical operation
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).